Abstract
Extensive research has been conducted to gain a deeper understanding of the deregulated metabolic pathways in the development of trisomy 21 (T21) or Down syndrome. This research has shed light on the hypothesis that oxidative stress plays a significant role in the manifestation of the T21 phenotype. Although in vivo studies have shown promising results in mitigating the detrimental effects of oxidative stress, there is currently a lack of introduced antioxidant treatment options targeting cognitive impairments associated with T21. To address this gap, a comprehensive literature review was conducted to provide an updated overview of the involvement of oxidative stress in T21. The review aimed to summarize the insights into the pathogenesis of the Down syndrome phenotype and present the findings of recent innovative research that focuses on improving cognitive function in T21 through various antioxidant interventions. By examining the existing literature, this research seeks to provide a holistic understanding of the role oxidative stress plays in the development of T21 and to explore novel approaches that target multiple aspects of antioxidant intervention to improve cognitive function in individuals with Down syndrome.
Graphical Abstract
The guides -base systematic review process (Hutton et al. 2015).
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Trisomy 21 (T21), also known as Down syndrome (DS), is the most prevalent genetic disorder affecting fetuses (Sherman et al. 2007; de Graaf et al. 2021; de Graaf et al. 2017; Murthy et al. 2007). T21 occurs at an incidence of approximately 1 in 700 to 1 in 1000 births worldwide (Irving et al. 2008; Mai et al. 2019). It is characterized by the presence of an extra copy of chromosome 21 and can result from various genetic abnormalities such as maternal non-disjunction, mosaic karyotype, Robertsonian translocation, or partial duplication of the critical region of chromosome 21(Hoeffer et al. 2007; Antonarakis et al. 2020; Akhtar and Bokhari 2021). Individuals with T21 exhibit distinctive features including cognitive impairment, muscle hypotonia, and dysmorphic characteristics (Lana-Elola et al. 2011; Korenberg et al. 1994; Korbel et al. 2009). Proper diagnosis and treatment of neurological complications are essential for optimizing the life expectancy and well-being of individuals with DS (Lott and Dierssen 2010). Given the multiple impairments associated with the presence of an additional chromosome 21, it is crucial to gain novel insights into the disrupted metabolic pathways, particularly those related to cognitive impairment improvement (Narasimhan et al. 2013; Jackson et al. 2019; Adelekan et al. 2012; Whooten et al. 2018; Hartley et al. 2015; Gardiner 2014). Understanding the functions of genes on chromosome 21 and their impact on cognitive impairment is of paramount importance (Ishihara and Akiba 2017). Gene mapping studies have identified lipid peroxidation, mitochondrial dysfunction, and impaired neurogenesis as potential factors contributing to the neuronal phenotype and cognitive impairment in DS. Recent clinical investigations have highlighted a connection between oxidative stress and cognitive deficits in individuals with T21 (Zis et al., n.d.; Lott 2012; Ishihara and Akiba 2017; Zafrilla et al. 2014). Consequently, there has been discussion regarding antioxidant interventions aimed at reducing the negative consequences of increased oxidative stress, such as lipid peroxidation, mitochondrial dysfunction, and disturbances in neurogenesis factor synthesis (Picca et al. 2020). Despite these findings, there is currently a lack of clinical management strategies or the introduction of novel treatment modalities specifically for T21 (Muchová et al. 2014). Consequently, multidirectional target analyses are still being explored, along with subsequent evaluations of their potential as DS biomarkers and therapeutic targets. Further research is needed to better understand the underlying mechanisms and to develop effective interventions to improve cognitive function and overall outcomes in individuals with T21.In this review, we examine the available data on the DS phenotype and highlight the emerging role of oxidative stress in its pathogenesis. Furthermore, we compare various antioxidant interventions that have been employed to address DS-related cognitive impairment, along with subsequent analysis of clinicopathological features. The review aims to shed light on the relationship between oxidative stress and the DS phenotype by examining relevant studies. It explores how oxidative stress may contribute to the cognitive impairments observed in DS and investigates different antioxidant strategies that have been utilized to mitigate these impairments. Through a comprehensive analysis of the literature, we assess the effectiveness of various antioxidant implementations in improving cognitive function in individuals with DS. This includes a consideration of the clinical and pathological features associated with these interventions, providing insights into their potential benefits and limitations. By summarizing and comparing the existing research, this review seeks to enhance our understanding of the interplay between oxidative stress and the DS phenotype, as well as provide valuable information on antioxidant approaches for addressing cognitive impairment in DS.
Materials and Methods
A systematic literature review was performed utilizing the PubMed database, adhering to the guidelines set forth by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and the Enhancing the QUAlity and Transparency Of health Research (EQUATOR) network (Hutton et al. 2015; Schiavo 2019). The review was conducted in accordance with a registered protocol in the PROSPERO database, with the registration number CRD42022302440. By following the PRISMA and EQUATOR network guidelines, as well as registering the review protocol in PROSPERO, this literature review strives to ensure a rigorous and transparent approach to synthesizing and analyzing the available evidence related to the research question or topic of interest.
The literature search was performed in February 2022, utilizing specific keywords related to the research topic. The keywords included trisomy 21, Down syndrome, oxidative stress, antioxidant capacity, lipid peroxidation, mitochondrial dysfunction, serine/threonine protein kinase, neurogenesis, antioxidant treatment, and clinical trials. During the review process, manuscripts that exhibited poor study design, lack of clearly defined eligibility criteria, irrelevant definition of exposures, contrasts, and outcomes, outdated studies, inconsequential characteristics of study participants, inadequate reporting of results, or a plurality of the study group were excluded. By applying these inclusion and exclusion criteria, the review aimed to ensure the inclusion of relevant and high-quality studies that provide valuable insights into the role of oxidative stress, antioxidant interventions, and associated clinical trials in trisomy 21 or Down syndrome. The rigorous evaluation of the selected manuscripts helps to maintain the integrity and validity of the review findings.
Mapping Chromosome 21: Is it an Indication for the Oxidative Status Research?
The T21 is considered a comprehensive and reliable model for conducting experimental studies on genotype–phenotype relationships (Salehi et al. 2007). Chromosome 21 harbors multiple genes that have been associated with Down syndrome (DS) phenotypes. These genes include Cu/Zn superoxide dismutase (SOD1), amyloid precursor protein (APP), Ets-2 transcription factors, Down Syndrome Critical Region 1 (DSCR1), stress-inducible factor, beta-secretase 2 (BACE2), and S100 calcium binding protein B (S100B) (Coskun and Busciglio 2012; Zewen Liu et al. 2017a, b, c)In addition, an aberrant gene expression profile is linked to the mitochondrial phenotype observed in DS, characterized by reduced respiratory efficiency, changes in mitochondrial morphology, altered oxidative metabolism, and impaired mitochondrial biogenesis (Izzo et al. 2017; Sobol et al. 2019) (Table 1).
Emerging evidence indicates that gene therapy holds promise as a potential approach to modulate enzymatic activities and counteract the detrimental effects of oxidative stress. This therapeutic strategy has shown successful outcomes in various neurodegenerative and neurological disorders (X. Zhu et al. 2021; Sun and Roy 2021). Mounting evidence supports the notion that disturbances in neurogenesis and oxidative stress play a significant role in the development of diverse neuronal abnormalities observed in individuals with DS (Walton et al. 2012; Nunomura et al. 2000; Helguera et al. 2013; Pagano and Castello 2012).
Oxidative Stress
A connection has been established between oxidative stress and neuronal cell apoptosis in the development of numerous neurodegenerative disorders (Fujita et al. 2012). The accumulation of reactive oxygen species (ROS) disrupts cellular signaling pathways and is linked to brain injury and the progression of neurodegenerative conditions (T.-F. Yuan et al., n.d.; Nunomura et al. 2000; Iannello et al. 1999). The presence of oxidative stress causes the impairment of the blood–brain barrier, depolarization of membranes, inhibition of membrane enzyme activity, and inadequate protein transport (Singh et al. 2019). The reduction in antioxidant capacity, along with impaired neurogenesis, has the potential to exacerbate nerve damage (Timme-Laragy et al. 2013).
Consequently, the supplementation of antioxidants in individuals with DS has the potential to offer protection against the progression of neuronal dysfunction. Promising findings have emerged from studies focusing on enhancing psychomotor development through the use of antioxidant interventions, particularly those based on phytochemical compounds derived from plants. These plant-derived alternative antioxidants (AOX) encompass various dietary phytochemicals such as polyphenols, quinones, flavonoids, catechins, coumarins, and terpenoids, which are considered crucial exogenous AOX.
Previous research has already demonstrated the ability of AOX administration to impede the advancement of neurodegenerative diseases. However, the precise mechanism of action of AOX has yet to be fully elucidated. Ongoing investigations are aimed at further understanding the specific ways in which AOX exert their protective effects in DS and other related conditions (Kumar and Khanum 2012). The existence and characterization of receptors or transporters for phytochemicals in brain tissues have yet to be definitively established, and the outcomes of clinical trials investigating the application of AOX may yield promising results for individuals with T21. Consequently, therapeutic options that encompass compounds with multiple targets are deemed viable for addressing diseases with multifactorial causes, such as DS (Baburamani et al. 2019).
In recent years, there has been a substantial body of research highlighting the neuroprotective potential of phytochemicals and antioxidants, as well as their positive impact on the prevention of neurodegenerative disorders (Gandhi and Abramov 2012; Perrone et al. 2007; Barone et al. 2017; Kurabayashi et al. 2019). The assessment of oxidative stress in DS facilitates a better comprehension of the underlying mechanisms contributing to cognitive impairment, thereby driving the exploration of novel and promising molecular targets for elucidating and mitigating neurodegeneration, starting from early human prenatal development (Yadav et al. 2022).
Human Prenatal Development
Perluigi et al. conducted a study that focused on analyzing triplicated chromosome 21, which contains several genes associated with oxidative stress. The researchers evaluated various oxidative stress markers, including protein carbonylation, protein-bound 4-hydroxy-2-nonenal (HNE), levels of total and oxidized glutathione (GSH), concentrations of heat shock protein (HSP) and thioredoxin (TRX), in amniotic fluid samples. The investigation utilized techniques such as slot-blot analysis, enzymatic assays, and Western blot. The study findings demonstrated that oxidative stress occurs early in pregnancies affected by trisomy 21 (T21), as evidenced by increased protein oxidation, lipid peroxidation, reduced levels of GSH and TRX, and the induction of the HSP response. These processes have been implicated in the DS phenotype, providing insights into the role of oxidative stress in T21 pathogenesis (Perluigi et al. 2011; Zis et al., n.d.; Slonim et al. 2009; Marcovecchio et al. 2021; Convertini et al. 2016). The oxidative stress markers were also assessed following the collection of maternal plasma and amniotic fluid samples from confirmed T21 pregnancies (Barone et al. 2018; Buczyńska et al. 2021; Pietryga et al. 2021). The study results revealed a significant increase in DNA/RNA oxidative stress damage products in amniotic fluid samples from pregnancies affected by T21 compared to euploid samples. However, no significant difference was observed in plasma measurements between the two groups (Buczyńska et al. 2021). In pregnancies affected by T21, the concentration of advanced glycation end products (AGE) was found to be reduced in both plasma and amniotic fluid samples compared to euploid pregnancies. Conversely, the antioxidant marker asprosin exhibited significantly higher concentrations in both plasma and amniotic fluid samples within the T21 group when compared to euploid pregnancies. The therapeutic mechanism of asprosin is believed to be associated with its beneficial effects on insulin resistance, oxidative stress, and neuropathy (M. Wang et al. 2019; Ozcan et al. 2022). Furthermore, the findings indicated that the concentrations of alpha-1-antitrypsin (A1AT) and 25-hydroxy vitamin D (25-OH vitamin D) were downregulated in cases of trisomy 21 (T21) aneuploidy. This suggests that the decreased A1AT concentration, coupled with exacerbated inflammatory processes and heightened oxidative stress observed in T21 pregnancies, may have a negative impact on multiple comorbidities, potentially contributing to the development of the DS phenotype (Buczyńska et al. 2021). The findings from this study suggest a hypothesis that oxidative stress primarily occurs within the fetus affected by T21 rather than in the maternal compartment. Additionally, it is proposed that the maternal antioxidant mechanisms may be inadequate to compensate for the antioxidant deficiencies induced by the developing T21 fetus (Buczyńska et al. 2021). It is crucial to emphasize that the impact of oxidative stress has already been observed during prenatal development. Therefore, when considering potential medications aimed at reducing oxidative stress, it is essential to ensure not only their effectiveness but also their safety for the developing fetus (Scott et al. 2020; Buczyńska et al. 2021; 2020).
T21 Childhood
In a following study conducted by Zitnanova et al., the concentration of oxidative stress markers was assessed using high-performance liquid chromatography (HPLC). The study revealed that the group of children with T21, consisting of 20 participants, exhibited higher levels of protein carbonyls in comparison to the healthy control group, which consisted of 18 individuals (Žitňanová et al. 2006). Conversely, the study found that the antioxidant capacity was comparable between the two groups. The primary focus of this investigation was to assess the hypothesis that individuals with T21 exhibit an elevated oxidative stress status (Žitňanová et al. 2006). Likewise, Kamatsu et al. conducted an assessment of the concentration of 8-hydroxy-2'-deoxyguanosine, an oxidative stress marker, in saliva samples obtained from individuals with T21. The findings of the study confirmed the presence of oxidative stress in T21 patients based on the elevated levels of the oxidative stress marker (Komatsu et al. 2013). In their antioxidant evaluation, He et al. discovered that the total superoxide dismutase (SOD) activity was significantly higher in the T21 group compared to healthy individuals. However, the activity of extracellular glutathione peroxidase (GPx3) was found to be reduced in the T21 group. These findings highlight the altered antioxidant enzyme activities observed in individuals with T21 compared to those without the condition (He et al. 2016). It can be inferred that oxidative stress not only contributes to congenital impairments but also has detrimental effects on various biological components (Sharifi-Rad et al. 2020). Due to prolonged exposure to oxidative stress during the prenatal period, it is postulated that a decline in the compensatory antioxidant capacity of cells may exacerbate oxidative-related comorbidities, including cognitive phenotypes. Subsequent in vivo studies have been conducted to investigate and validate these hypotheses.
In Vivo Studies and Potential Therapies
Several DS mouse models have been developed to study the neurobiological and cognitive impairment mechanisms implicated in T21 (Gupta, Dhanasekaran, and Gardiner 2016; Meng, Wang, and Ma 2018; Belichenko et al. 2015). The Ts65Dn and Ts1Cje mouse models possess an additional small region on chromosome 16 that harbors genes orthologous to those found on triplicated human chromosome 21 (D. Hamlett et al. 2015; Marechal et al. 2019; Revilla and Martínez-Cué 2020). In their study, Ishihara et al. utilized T21 mouse models (Ts1Cje and Ts2Cje) to investigate oxidative stress. The results demonstrated an elevation in ROS concentration in the brains of mice with DS compared to those without the condition. Additionally, the expression of oxidatively modified proteins and lipid peroxidation-derived products, such as 13-hydroperoxy-9Z,11E-octadecadienoic acid and 4-hydroxy-2-nonenal, was significantly increased in the brains of the T21 mouse models. These findings provide further evidence of oxidative stress in the context of DS (Ishihara et al. 2009). The study examined various in vivo protocols aimed at antioxidant therapy. The findings demonstrated that prenatal treatment had a positive impact on brain development. However, it should be noted that despite the promising results obtained, these findings have not yet been translated into clinical trials (Keck-Wherley et al. 2011; Gardiner 2014; Najas et al. 2015; Revilla and Martínez-Cué 2020). Recent data has indicated that the administration of the antidepressant fluoxetine via prenatal infusion in Ts65Dn mice resulted in improved neuronal development in the brain (Kuehn 2016; Fayçal Guedj, Bianchi, and Delabar 2014). In this case, fluoxetine supplementation in Ts65Dn mice improved the development of brain neurons, where rapamycin and α-tocopherol in preclinical studies markedly reduced lipid peroxidation and improved cognition in preclinical DS mouse models (Duval, Vacano, and Patterson 2018; Shichiri et al. 2011). Guedj et al. conducted a study demonstrating that the administration of the antioxidant apigenin offers protection against elevated oxidative stress and imbalances in total antioxidant capacity in fetal cells derived from human amniotic fluid with T21 and in the Ts1Cje mouse model (Faycal Guedj et al. 2020; Warkad et al. 2021). This study suggests that apigenin has a pleiotropic effect, leading to the activation of pro-proliferative and pro-neurogenic factors including Mki67, nestin, Sox2, and Pax6. Additionally, apigenin appears to reduce the concentrations of pro-inflammatory cytokines, such as interferon gamma, interleukin 1A, and interleukin 12P70, by inhibiting nuclear factor-κB signaling. Furthermore, it increases the concentrations of anti-inflammatory cytokines interleukin 10 and interleukin 12P40, while also enhancing the expression of angiogenic and neurogenesis factors, such as vascular endothelial growth factor A and interleukin 7 (Faycal Guedj et al. 2020).
Strengths and Limitations of Clinical Trial
Although there is substantial evidence supporting the occurrence of oxidative stress in individuals with T21 throughout various stages of development, clinical trials conducted thus far have not yielded significant advancements in clinical management for this condition (S. E. Lee et al. 2020). A hypothesis can be put forward that prenatal antioxidant intervention may have a positive effect in mitigating cognitive impairment. This hypothesis suggests that by identifying deregulated metabolic pathways, new diagnostic targets can be identified, allowing for the implementation of optimized treatments, including during fetal life, with the aim of providing protective effects for the brain development of individuals with T21 (Fayçal Guedj, Bianchi, and Delabar 2014). Prospective clinical studies involving large cohorts of children with T21 in the future may provide valuable insights into the impact of antioxidant therapies and diet on the clinical manifestations of this syndrome. Additionally, the potential of antioxidant interventions to slow down the progression of dementia and other neurodegenerative diseases in individuals with T21 warrants further investigation. Consequently, there is a demand for the development of new antioxidants with diverse intervention strategies. Furthermore, the intricacies of oxidative remodeling in metabolic components and pathways in individuals with T21 remain incompletely understood and require further exploration (Gardiner 2014; Lott 2012; Fayçal Guedj, Bianchi, and Delabar 2014). The utilization of a redox-modulating strategy to mitigate cognitive impairment holds promise as a novel therapeutic approach. However, a comprehensive comprehension of ROS-mediated signaling in trisomy is essential to facilitate the development of innovative therapeutic interventions (Bourgonje et al. 2020).
However, oxidative stress is just one of the pathways associated with congenital disabilities in Down syndrome DS. The absence of a comprehensive DS mouse model hinders the translation of treatments to DS patients. Consequently, predicting the dose–response relationship, potential side effects, and assessing cognitive function improvement between mouse and human models remains challenging. Overcoming these challenges through rigorous experimental design and interpretation of results in both mouse and human studies could potentially minimize the risk of clinical trial failures and contribute to the effective reduction of cognitive defects in DS treatment.
Lipid Peroxidation
Lipid peroxidation is a cascading chain reaction wherein by-products, such as radicals derived from fatty acids, interact with other free fatty acids, resulting in the formation of lipid peroxides (LPOs) (Einor et al. 2016; Nishizawa et al. 2021; Gasparovic et al. 2013; Gago-Dominguez and Castelao 2008). Moreover, the presence of LPOs enhances the reactivity of non-radical compounds by facilitating their interaction with singlet oxygen or oxyradicals. This heightened reactivity of non-radical compounds plays a significant role in modulating the redox potential (Barone et al. 2017; Ramana et al. 2017; Juan et al. 2021; Marnett 2002). The quantification of oxidized low-density lipoprotein (o-LDL), lipid peroxide (LPO), 4-hydroxynonenal (HNE), and malondialdehyde (MDA) serves as reliable indicators of lipid peroxidation, functioning as independent biomarkers (J et al. 2020; Zhihua Liu et al. 2017a, b, c; Yuan et al. 2019). Lipids play a crucial role in the structural and functional integrity of the central nervous system, accounting for approximately 60% of the constituents found in brain cells (Barón-Mendoza and González-Arenas 2022). Existing literature suggests that lipid peroxidation plays a significant role in the development of neurodegenerative diseases. It can modulate various aspects, including the physical properties of cell membranes, secondary messenger activity, and gene expression regulation. These implications are also relevant in the context of analyzing T21 (Strydom et al. 2018). Lipid peroxidation plays a crucial role in the development of cognitive impairment, and it can act as a signal integrator that translates various signals into metabolic responses. Additionally, it has the potential to impact cellular physiology and behavior on multiple levels, thereby disrupting neurogenesis processes (Müller et al. 2009).
Prenatal Development
Perluigi et al. identified proteins that are critically relevant in T21 pathogenesis and are involved in iron homeostasis (ceruloplasmin and transferrin), lipid metabolism (zinc-a2-glycoprotein, retinol-binding protein 4, and apolipoprotein A1), and inflammation (complement C9,a-1B-glycoprotein, collagen alpha-1 V chain) (Perluigi et al. 2011). Western blotting was performed to investigate amniotic fluid samples collected from 10 individuals with T21 pregnancy and 10 individuals with a healthy fetus, serving as a control group (Perluigi et al. 2011). The comparison of maternal plasma metabolic fingerprints between euploid and T21 pregnancies revealed lower levels of five metabolites in the T21 group. Among these metabolites, linoleamide and piperine concentrations demonstrated the highest clinical significance (Parfieniuk et al. 2018). Linoleamide, also known as linoleic acid amide, participates in the lipid metabolism and specifically contributes to lipid peroxidation processes (Parfieniuk et al. 2018; Ioannou et al. 2019; Taha 2020). The reduced concentration of piperine, known for its anti-inflammatory, antioxidant, and lipid peroxidation-protective properties, has been linked to the ineffective neuroprotective characteristics observed in individuals with T21 (Parfieniuk et al. 2018; Yang et al. 2015; Azam et al. 2022; Manap et al. 2019).
Childhood
Research conducted on T21 children has demonstrated elevated levels of oxidative stress and lipid peroxidation. In a study conducted by He et al., it was observed that T21 children exhibited higher concentrations of MDA compared to individuals without the trisomy 21 condition (He et al. 2016). A similar finding was reported in the study conducted by Manna et al. The assessment of plasma lipid peroxidation markers, including F2-isoprostanes, F2-dihomo-isoprostanes, and F4-neuroprostanes, revealed increased levels of lipid peroxidation in the T21 group (Manna et al. 2016). These disruptions are believed to be implicated in neurodegeneration and cognitive deterioration. Barone et al. provided evidence of the involvement of beta-amyloid (Aβ) and tau hyperphosphorylation in T21 neuropathy. Additionally, the accumulation of HNE was observed in the brain of individuals with T21 compared to the control tissue (Barone et al. 2017). The accumulation of HNE is thought to have a significant impact on the disruption of metabolic pathways, leading to abnormalities in glucose metabolism, neuronal trafficking, and antioxidant responses (Barone et al. 2017).
Potential Treatment
Highlighting the significance of oxidative stress and lipid peroxidation, a study conducted by Ordonez et al. proposed that regular exercise could potentially reduce oxidative stress and subsequent lipid peroxidation in individuals with T21. In this particular study, a 12-week training program consisting of three sessions per week was administered to thirty-one male adolescents with T21. The findings demonstrated a notable reduction in the concentration of MDA, indicating a decrease in lipoperoxidation (Javier Ordonez and Rosety-Rodriguez 2007). Pharmacological investigations have been conducted utilizing the Ts65Dn mouse model of DS. One study involved administering α-tocopherol to pregnant Ts65Dn female mice starting from the day of conception throughout pregnancy, which resulted in a reduction in cognitive impairment. Furthermore, young mice were supplemented with α-tocopherol from birth until the completion of the behavioral testing period. The findings of this study indicated that α-tocopherol supplementation led to a mitigated cognitive impairment, accompanied by decreased lipid peroxidation levels when compared to the control group (Shichiri et al. 2011). In addition, supplementation with rapamycin, an inhibitor of the mammalian target of rapamycin complex 1, in Ts65Dn mice has been shown to decrease lipoxidation-mediated protein damage. This suggests that rapamycin could serve as a potential therapeutic approach to reduce the risk of developing Alzheimer's disease (AD) in individuals with DS (Curtis et al. 2020; Di Domenico et al. 2019).
Future Perspectives
Certain lipid metabolic pathways directly influence neuronal maturation and differentiation (Knobloch and Jessberger 2017). Hence, the prevention of lipid peroxidation may potentially lead to a decrease in cognitive impairment. However, further studies are required to assess the impact of such interventions. Currently, no clinical trials have been conducted specifically targeting the reduction of lipid peroxidation through appropriate supplementation. It could be hypothesized that substances like α-tocopherol or herbal supplements such as berberine might be considered as treatment options for prenatal or adult individuals with T21, based on promising results that could be obtained from well-controlled clinical trials (Hasanein et al. 2017).
Mitochondrial Dysfunctions
Recent research has revealed that oxidative stress-induced mitochondrial dysfunction plays a significant role in both neurodevelopment and neurodegenerative disorders (Zana et al. 2007; Emiliano Zamponi et al. 2018; Ma 2013; Kura et al. 2019).
In Vivo Studies
Gimeno et al. conducted a study that provided evidence of accumulated damage in mitochondria of T21 fibroblasts, which was found to be associated with an elevated oxidative stress status (Antonaros et al. 2021; Liu et al. 2017a, b, c; Gimeno et al. 2014). Subsequent studies investigating mitochondrial alterations in individuals with T21 have revealed several findings. These studies have shown that T21 is associated with reduced mitochondrial structure and vascularization, as well as decreased connectivity within the mitochondrial network, when compared to normal mitochondria (Zamponi and Helguera 2019; Pallardó et al. 2010; Izzo et al. 2017; Perluigi and Butterfield 2012). Similar structural and functional mitochondrial defects have been observed in other neurodegenerative diseases (Buneeva et al. 2020; Bose and Beal 2016; Guo et al. 2013; Singh et al. 2019). The abnormal redox potential observed in individuals with T21 is not solely attributed to the overproduction of ROS, but also to the insufficient protection provided by histones. Consequently, this imbalance contributes to a higher mutation rate in mitochondrial DNA (mtDNA) (Coskun and Busciglio 2012; Hahn and Zuryn 2019). Mitochondria are recognized as essential defenders against oxidative stress, and when there is an increased damage to mtDNA, it compromises their ability to adequately counteract the detrimental effects of ROS. As a result, the reduction of negative consequences caused by ROS becomes insufficient (Ježek et al. 2018; Picca et al. 2020; Alexeyev et al. 2013). Recently, the molecular mechanisms responsible for mitochondrial damage and energy deficits were identified and characterized in several T21-derived human cells and animal models (Picca et al. 2020). Helguera et al. conducted studies on human T21 astrocytes and neuronal cultures and observed a decrease in mitochondrial redox balance, coupled with impaired membrane potential excitability. These disturbances were found to be responsible for the adaptive downregulation of mitochondrial functions. This downregulation serves as a protective mechanism, preventing excessive oxidative damage and preserving essential cellular functions (Helguera et al. 2013). Kim et al. conducted a study that demonstrated decreased protein levels of mitochondrial complexes I, III, and V in T21 brain tissue. This reduction in mitochondrial complex proteins was associated with an increased percentage of neuronal cell apoptosis (Kim et al. 2001). Accordingly, the study performed by Coskun et al. showed that mtDNA mutations were also found in T21 brain tissues (Coskun and Busciglio 2012). Neurons rely heavily on optimal mitochondrial function as mitochondria are responsible for generating cellular adenosine triphosphate (ATP) through oxidative phosphorylation. ATP production is crucial for supporting high-energy metabolism in neurons (Ullah et al. 2021). In a study conducted by Valenti et al., using the Ts65Dn mouse model, it was demonstrated that administering the polyphenol 7,8-dihydroxyflavone (7,8-DHF) to neonatal mice at a dose of 5 mg/kg/day led to a complete restoration of brain bioenergetic dysfunction and a reduction in the levels of oxygen radicals. These findings suggest that 7,8-DHF improves mitochondrial bioenergetics and mitigates mitochondria-related neurodevelopmental abnormalities in individuals with DS (Valenti et al. 2021).
Future Perspectives
To gain a comprehensive understanding of mitochondrial dysfunction observed during the development of T21, further exploration of fundamental mitochondrial biology is necessary. This includes investigating the mechanisms responsible for maintaining mitochondrial dynamics, eliminating defective organelles, and safeguarding the integrity of mitochondrial DNA (mtDNA) during maternal inheritance and cell division. By delving into these aspects, researchers can shed light on the underlying mechanisms contributing to mitochondrial dysfunction in T21 and potentially identify targets for therapeutic interventions (Marcovecchio et al. 2021). Preserving the connectivity of the mitochondrial network is vital as it represents a significant contributing factor to proper cellular function in individuals with T21. The integrity of the mitochondrial network plays a critical role in various cellular processes, including energy production, calcium homeostasis, and apoptotic signaling. Disruptions or impairments in mitochondrial network connectivity can lead to detrimental effects on cellular physiology and contribute to the pathogenesis of T21. Therefore, ensuring the protection and maintenance of a well-connected mitochondrial network is essential for mitigating the impact of mitochondrial dysfunction in T21(Picca et al. 2020; E. Zamponi and Helguera 2019; Valenti et al. 2018; Izzo et al. 2018). Therefore, the implementation of combined therapeutic strategies that target both mitochondrial function and antioxidative processes holds significant potential for the development of new treatment approaches in the management of conditions associated with mitochondrial dysfunction and oxidative stress, such as T21. By addressing these intertwined factors simultaneously, it may be possible to synergistically enhance cellular resilience, improve mitochondrial bioenergetics, and counteract the harmful effects of oxidative stress. Such combined approaches could involve the use of mitochondrial-targeted therapies, antioxidants, and interventions aimed at promoting cellular antioxidant defense mechanisms. The integration of these strategies has the potential to provide more comprehensive and effective treatment options for individuals with T21 and related conditions (Valenti et al. 2018).
DS Cognitive Features
Recent study evaluating the human DS brain transcriptome showed the deregulation of genes involved in neuronal differentiation (Olmos-Serrano et al. 2016). The specific gene expression alterations have been associated with axonal myelination and altered psychomotor development in DS individuals (Ponroy Bally and Murai 2021; Olmos-Serrano et al. 2016) Table 2 substantiates these findings (Table 2).
While many cells are able to overcome increased oxidative stress, neurons in the brain are especially vulnerable to oxidative imbalance (Wang and Michaelis 2010). The postmortem study conducted by Annus et al. revealed several characteristic features of the DS brain. These features include reduced brain weight, a lower number and depth of cerebral sulci (the grooves on the surface of the brain), enlarged ventricles (cavities within the brain), and hypoplasia (underdevelopment) of the brainstem, cerebellum, frontal lobes, and temporal lobes. These structural abnormalities are commonly observed in individuals with DS and contribute to the cognitive and neurological impairments associated with the condition. Understanding the specific brain alterations in DS can provide valuable insights into the underlying pathology and guide further research and potential interventions aimed at improving the quality of life for individuals with DS (Annus et al. 2017). Psychopathology in T21 differs from the abnormalities of other intellectual disability syndromes (Onnivello et al. 2022). Among DS individuals, increased risk of AD, as well as low-intensity behavioral and emotional disorders have been observed when compared to euploid subjects (Silverman 2007).
Accordingly, Annus et al. observed that adults with DS are able to tolerate significant cortical atrophy in the presence of amyloid without experiencing detrimental effects on their cognitive function. In this study, the brains of 46 adults with DS and 30 healthy controls underwent structural and amyloid imaging. The findings suggest that the relationship between brain structure, amyloid deposition, and cognitive function may differ in individuals with DS compared to the general population (Annus et al. 2017). This study revealed a distinct neurodevelopmental phenotype in the DS brain, characterized by a thicker cortical ribbon, particularly in the frontal and occipital lobes, and a thinner motor cortex. Additionally, compared to the general population, individuals with DS exhibited disproportionately larger putamina and smaller hippocampi, which likely result from abnormal brain development and maturation. The findings underscore the complexity of cognitive impairment formation and the influence of increased oxidative stress in exacerbating these disorders. In an effort to identify T21 brain regions most susceptible to oxidative stress, a study conducted by Head et al. demonstrated that T21 newborns face higher levels of oxidative stress compared to euploid individuals. Interestingly, this process promotes the survival of cellular phenotypes that are more resistant to ROS. These results shed light on the interplay between oxidative stress and cognitive outcomes in DS and provide valuable insights into potential targets for therapeutic interventions (Head et al. 2016). The study conducted by Cenini et al. established a link between oxidative damage in the frontal cortex and the presence of Aβ plaques associated with DS. The frontal cortex was examined in 70 autopsied brains, including 29 euploid subjects and 41 DS patients. The findings demonstrated an elevated concentration of soluble and insoluble Aβ peptides, as well as an accumulation of oligomers, in the frontal cortex of DS patients. This directly contributes to the development of AD. Importantly, the study also revealed a correlation between protein carbonyls, which are formed through oxidative modification induced by ROS, and amyloid levels. These results highlight the connection between oxidative stress, amyloid pathology, and cognitive decline in individuals with DS, providing valuable insights for understanding the underlying mechanisms and potential targets for therapeutic interventions (Cenini et al. 2012).
T21-Related Neuronal Phenotype: A Bridge Toward Alzheimer Disease
T21 is characterized by brain hypotrophy and intellectual disability starting from the early life stages (Martinez et al. 2021; Takano et al. 2017; X. Lu, Yang, and Xiang 2022). This defect is caused by reduced acquisition of a neuronal phenotype and an increase in the acquisition of an astrocytic phenotype by neural progenitor cells (J. Lu, Sheen, and Shee 2013; Busciglio and Yankner 1995). In patients with T21, the development of dendrites with widespread branches was not observed, even at the time of fetal life (Becker et al. 1986; Iqbal and Eftekharpour 2017). Additionally, the upregulation of the amyloid precursor protein, located on chromosome 21, leads to the accumulation of Aβ plaques, which is associated with the development of AD and, in many instances, cerebral amyloid angiopathy (Nunomura et al. 2000). The neuropathology of DS is multifaceted and exhibits significant variability. The distinctive features of the neurodegenerative process include dysregulated free radical metabolism and impaired mitochondrial function, both of which contribute to the onset of AD in individuals with DS by middle age (Lott and Head 2001). Interestingly, elevated levels of oxidative stress could also be caused by increased release of amyloid beta-peptide (Perluigi and Butterfield 2012). Numerous studies have observed that individuals with T21 exhibit elevated concentrations of Aβ in both plasma and brain tissues, and this increase has been found to be negatively correlated with patient age (Schupf et al. 2010; “Down Syndrome and Beta-Amyloid Deposition: Current Opinion in Neurology” 2004). Furthermore, in the study conducted by Anandatheerthavarada et al., it was found that Aβ specifically targeted the mitochondria of cortical neuronal cells and certain regions of the brain, leading to neuronal changes associated with AD (Anandatheerthavarada et al. 2003; Busciglio et al. 2007). Furthermore, considering the genetic similarities between DS and AD, as the genes responsible for AD are encoded by chromosome 21, it offers an intriguing area of research for understanding many unresolved issues. Given the shared neuropathology, clinical presentation, and risk factors between DS and AD, their cognitive profiles also exhibit similarities. In a study conducted by Dick et al., it was discovered that the neuropsychological profiles of participants with DS and AD were remarkably similar (Dick et al. 2016).
Improving T21-Related Cognitive Impairments
In Vitro Studies
Currently, only a limited number of therapeutics and nutraceuticals have been examined using the Ts65Dn mouse model, which represents DS, with the objective of enhancing learning and memory functions (Galati et al. 2018; Choong et al. 2015; Faycal Guedj et al. 2020). Nevertheless, these studies are characterized by many limitations (Das and Reeves 2011; Rueda et al. 2012). First of all, orthologs of chromosome 21 genes map to segments of three mouse chromosomes, Mmu16, Mmu17, and Mmu10 (Gupta et al. 2016). Furthermore, it is challenging to identify dosage-sensitive genes linked to DS-related phenotypes using mouse models. As a result, DS phenotypes may be attributed to the dysregulated expression of extensive chromosomal domains across the entire genome (Antonarakis et al. 2020). Nonetheless, mouse models that encompass a broader representation of the genetic basis for DS can be valuable in enhancing our understanding of the molecular mechanisms underlying the diverse clinical characteristics of DS and ultimately leading to advancements in brain function (Das and Reeves 2011).
In a study conducted by Zhu et al., the pharmacological suppression of the integrated stress response (ISR) gene resulted in a reduction in congenital impairments. The research aimed to inhibit the ISR-inducing double-stranded RNA-activated protein kinase by enhancing the function of the eukaryotic translation initiation factor 2-eukaryotic translation initiation factor 2B complex (eIF2-eIF2B). This intervention facilitated proper translation and synaptic transmission, leading to increased synaptic activity. By silencing the ISR, significant improvements were observed in the formation of long-term memories in mice with DS (Zhu et al. 2019). Building upon the previously published studies that focused on the selective suppression of mitochondrial complex proteins and the reduction of oxidative stress through ISR silencing, additional research holds the potential to integrate multiple disrupted pathways. This would contribute to a comprehensive understanding of the biological effects of gene inhibition in DS, potentially paving the way for the development of gene therapy interventions (Zhang et al. 2021). It can be hypothesized that by comprehending the neuroanatomical features of the DS brain and implementing tailored therapeutic approaches, it may be possible to mitigate cognitive impairment and enhance cognitive functions.
Furthermore, various studies have explored strategies to enhance neurological functions in T21 mice through the promotion of neurogenesis. In a study conducted by Xu et al., the effectiveness of hyperbaric oxygen (HBO) therapy was evaluated using rat middle cerebral artery occlusion. The results demonstrated neuroprotective effects and improvements in neuronal function (Xu et al. 2016). HBO treatment was found to stimulate neurogenesis and enhance neurofunctional recovery at day 42. These beneficial effects were attributed to a reduction in ROS synthesis, and when ROS levels were decreased, the observed improvements were reversed (Ahmadi and Khalatbary 2021). Profiling additional neurogenesis factors could facilitate the advancement of medical treatments for T21. It is possible to hypothesize that inhibiting ROS in T21 pregnancies could lead to improved fetal brain development (S. E. Lee et al. 2020; Revilla and Martínez-Cué 2020). Additional research and clinical trials are needed to validate this therapeutic strategy in humans, which could initiate T21 prenatal therapy.
In vivo studies
In vitro studies provide a basis for future clinical trials in humans. Subsequent studies on children with DS, in which α-tocopherol was supplemented at a dose of 400 IU/day, showed a significant decrease in urinary 8-hydroxy-2'-deoxyguanosine (8OHdG) concentrations. This suggests that α-tocopherol supplementation in the diets of children with DS may alleviate oxidative stress at the DNA level (Mustafa Nachvak et al. 2014). Table 3 summarizes the most crucial reports of cognitive impairment improvement and the available data from completed clinical trials (Table 3).
Future therapeutic testing should investigate whether a single-target therapy or combination therapy targeting oxidative stress is sufficient to overcome T21 cognitive impairment.
Future Perspectives
DYRK1A: Is the Molecular Signature of DS Phenotype Revealed?
In light of the challenges in drug development, genetic validation of drug targets has gained popularity, particularly in the management of complex trisomy disorders. Among the candidate genes associated with the characteristic phenotype of individuals with T21, DYRK1A, located on DSCR1, has emerged as the most promising target.
DYRK1A Inhibition—In Vitro Studies
To date, the inhibition of DYRK1A has shown the most promising results; however, several limitations still exist (Hibaoui et al. 2014). Garcia-Cero et al. demonstrated in a Ts65Dn model that increased expression of the DYRK1A gene plays a crucial role in various neurodegenerative processes observed in DS (García-Cerro et al. 2017; W et al. 2014). The overexpression of DYRK1A in T21 brains may contribute directly to early-onset neurofibrillary degeneration through tau hyperphosphorylation and indirectly through the phosphorylation of alternative splicing factors (Wegiel et al. 2011). Another recent study revealed the modulatory effects of natural polyphenols found in green tea on the DYRK1A kinase (Muchová, Žitňanová, and Ďuračková 2014). Consequently, DYRK1A inhibition has shown beneficial effects in mouse models of DS, including improvements in cognitive behavior. Pharmacological inhibition of DYRK1A has been achieved through treatment with epigallocatechin gallate (EGCG), yielding positive results in terms of alleviating cognitive impairment in transgenic mice overexpressing Dyrk1a and Ts65Dn mice (Hibaoui et al. 2014; J et al. 2020; Souchet et al. 2015; Stagni et al. 2016).
Clinical Trials of DYRK1A Inhibitor
In the first clinical study, DS patients (n = 31; aged 14–29 years) were enrolled and supplemented with EGCG (oral dose of 9 mg/kg/day) or placebo over a 3-month period. The intervention with EGCG showed improvements in visual recognition memory, working memory performance, psychomotor speed, and social functioning in individuals with T21(De la Torre et al. 2014). In the second clinical study, DS patients (n = 84; aged 16–34 years) were included, and the impact of cognitive training combined with EGCG supplementation (oral dose of 600 mg/day for participants weighing 50–75 kg or 800 mg/day for participants weighing 75–100 kg) was evaluated over a 12-month period. The combination of EGCG treatment and cognitive training resulted in improvements in visual recognition memory, inhibitory control, and adaptive behavior in the study group. Neuroimaging analysis also demonstrated enhancements in functional connectivity and cortical excitability (de la Torre et al. 2016; Feki and Hibaoui 2018). There is strong evidence supporting the involvement of DYRK1A not only in cognitive deficits associated with T21 but also in Alzheimer's disease (AD). Similar factors related to neuroinflammation and oxidative damage have been studied in both DS and AD individuals, leading to the early onset of dementia observed between the ages of 30 and 39(Becker et al. 1986; Hempel et al. 2015; Galceran et al. 2003). DYRK1A clearly plays a significant role as a common neurodegenerative factor, and therefore, studying the pathogenesis of DS will also contribute to the understanding of the pathogenesis of other neurodegenerative diseases.
Clinical Trials of DYRK1A Inhibitor Limitation
Despite the promising results obtained during in vivo studies, further DS treatment protocols aiming to inhibit the DYRK1A expression have been not proposed or recommended (Fayçal Guedj, Bianchi, and Delabar 2014; Faycal Guedj et al. 2020). Accordingly, due to limited data, it is still challenging to draw definitive conclusions about the effectiveness of pharmacological interventions for cognitive decline in individuals with DS. However, it is not possible to selectively inhibit DYRK1A expression. Therefore, EGCG acts as a mimic of multiple kinase inhibitors simultaneously (Bain et al. 2007). Moreover, the EGCG used in clinical trials is typically supplemented as green tea extracts, which contain EGCG along with various other compounds, including other catechins. Additionally, in the review conducted by Long et al., concerns regarding potential side effects and the lack of effectiveness, particularly due to flawed research planning, have been discussed (Long et al. 2019).
Discussion
Neuropharmaceutics represents the most promising avenue for addressing cognitive impairments among DS patients, making it the largest potential growth sector in the pharmaceutical industry (Pardridge 2007; Capsoni and Cattaneo 2022). Due to the brain's effective protection by the blood–brain barrier (BBB), the administration of pharmacological agents with intracerebral biological activity poses a challenge. In this regard, intranasal delivery emerges as a viable solution in neuropharmaceutics. This approach enables the direct delivery of medications to the brain, bypassing systemic effects and potential barriers associated with the BBB (Stagni et al. 2015). Interesting findings have emerged from studies conducted by Capsoni et al. and Rosenbloom et al., highlighting the potential of intranasal delivery as a therapeutic approach for DS patients. In Capsoni et al.'s study, intranasal administration of human nerve growth factor painless (hNGFp) was performed in Ts65Dn mice at an early stage, before the accumulation of amyloid precursor protein (APP) leading to neurodegeneration. This treatment effectively reduced astrogliosis, dystrophic microglia, and promoted neurogenesis, demonstrating a potent neuroprotective effect on early DS phenotypic deficits and dementia (Capsoni and Cattaneo 2022). In the study conducted by Rosenbloom et al., the effects of intranasal insulin application were evaluated in DS patients aged 35 years and above. The findings of this study indicated that the treatment was safe and well-tolerated among DS patients, and it showed potential for cognitive improvement and memory retention. However, further research with larger study cohorts is still necessary to establish the effectiveness of this approach (Rosenbloom et al. 2020).
Conclusions
Studies investigating the impact of oxidative stress on the occurrence of congenital fetal impairments in T21 patients have revealed a complex interplay of multiple metabolic pathways. Despite extensive research, it has not been possible to determine the potential of antioxidant supplementation in reducing cognitive impairment in T21 individuals. However, the integration of various oxidative stress-related pathways holds promise for the discovery of novel therapies in the future. In the coming decades, the challenges in the field of T21 will involve not only identifying effective therapies to mitigate cognitive defects but also understanding the molecular and cellular mechanisms underlying the characteristic phenotype resulting from genetic triplication. Exploring multitargeted antioxidant interventions in DS individuals will provide insights into the molecular and cellular mechanisms governing their nervous system function, leading to the discovery of potential therapies to overcome cognitive impairment. Among the clinical trials conducted to date, the inhibition of DYRK1A combined with cognitive training has shown significant improvements in visual recognition memory, inhibitory control, and adaptive behavior in adults with T21. Moreover, novel techniques such as intranasal delivery have been evaluated to improve cognitive impairments in DS individuals, with promising results. However, further studies in this field are still required.
Availability of Data and Materials
All data generated or analysed during this study are included in this published article.
References
Adelekan T, Magge S, Shults J, Stallings V, Stettler N (2012) Lipid profiles of children with down syndrome compared with their siblings. Pediatrics. https://doi.org/10.1542/peds.2011-1262
Ahmadi F, Khalatbary A (2021) A review on the neuroprotective effects of hyperbaric oxygen therapy. Med Gas Res 11(2):72. https://doi.org/10.4103/2045-9912.311498
Akhtar F, Bokhari SRA (2021) Down Syndrome. The 5-minute pediatric consult, 8th Edn (pp 306–367). https://doi.org/10.1017/9781316671863.043.
Alexeyev M, Shokolenko WG, LeDoux S (2013) The maintenance of mitochondrial DNA integrity—critical analysis and update. Cold Spring Harb Perspect Biol. https://doi.org/10.1101/CSHPERSPECT.A012641
Anandatheerthavarada HK, Biswas G, Robin MA, Avadhani NG (2003) Mitochondrial targeting and a novel transmembrane arrest of Alzheimer’s amyloid precursor protein impairs mitochondrial function in neuronal cells. J Cell Biol 161(1):41–54. https://doi.org/10.1083/JCB.200207030
Annus T, Wilson LR, Acosta-Cabronero J, Cardenas-Blanco A, Hong YT, Fryer TD, Coles JP et al (2017) The Down syndrome brain in the presence and absence of fibrillar β-amyloidosis. Neurobiol Aging 53:11–19. https://doi.org/10.1016/J.NEUROBIOLAGING.2017.01.009
Antonarakis SE, Skotko BG, Rafii MS, Strydom A, Pape SE, Bianchi DW, Sherman SL, Reeves RH (2020) Down syndrome. Nat Rev Dis Primers. https://doi.org/10.1038/s41572-019-0143-7
Antonaros F, Zenatelli R, Guerri G, Bertelli M, Locatelli C, Vione B, Catapano F et al (2021) The transcriptome profile of human trisomy 21 blood cells. Hum Genomics 15(1):1–14. https://doi.org/10.1186/S40246-021-00325-4/TABLES/3
Azam S, Park J-Y, Kim I-S, Choi D-K (2022) Piperine and its metabolite’s pharmacology in neurodegenerative and neurological diseases. Biomedicines 10(1):154. https://doi.org/10.3390/BIOMEDICINES10010154
Baburamani AA, Patkee PA, Arichi T, Rutherford MA (2019) New approaches to studying early brain development in Down syndrome. Dev Med Child Neurol. https://doi.org/10.1111/dmcn.14260
Baburamani AA, Vontell RT, Uus A, Pietsch M, Patkee PA, Wyatt-Ashmead Jo, Chin-Smith EC et al (2020) Assessment of Radial Glia in the Frontal Lobe of Fetuses with down Syndrome. Acta Neuropathol Commun 8(1):1–17. https://doi.org/10.1186/S40478-020-01015-3/FIGURES/6
Bain J, Plater L, Elliott M, Natalia Shpiro C, Hastie J, Mclauchlan H, Iva Klevernic J, Arthur SC, Alessi DR, Cohen P (2007) The selectivity of protein kinase inhibitors: a further update. Biochem J 408(Pt 3):297. https://doi.org/10.1042/BJ20070797
Barbiero L, Benussi L, Ghidoni R, Alberici A, Russo C, Schettini G, Pagano SF et al (2003) BACE-2 Is Overexpressed in Down’s Syndrome. Exp Neurol 182(2):335–345. https://doi.org/10.1016/S0014-4886(03)00049-9
Barón-Mendoza I, González-Arenas A (2022) Relationship between the Effect of Polyunsaturated Fatty Acids (PUFAs) on Brain Plasticity and the Improvement on Cognition and Behavior in Individuals with Autism Spectrum Disorder. Nutr Neurosci 25(2):387–410. https://doi.org/10.1080/1028415X.2020.1755793
Barone, Eugenio, Andrea Arena, Elizabeth Head, D. Allan Butterfield, and Marzia Perluigi. 2018. “Disturbance of Redox Homeostasis in Down Syndrome: Role of Iron Dysmetabolism.” Free Radical Biology and Medicine. Elsevier Inc. Doi: https://doi.org/10.1016/j.freeradbiomed.2017.07.009.
Barone, Eugenio, Elizabeth Head, D. Allan Butterfield, and Marzia Perluigi. 2017. “HNE-Modified Proteins in Down Syndrome: Involvement in Development of Alzheimer Disease Neuropathology.” Free Radical Biology and Medicine. Elsevier Inc. Doi: https://doi.org/10.1016/j.freeradbiomed.2016.10.508.
Becker LE, Armstrong DL, Chan F (1986) Dendritic Atrophy in Children with Down’s Syndrome. Ann Neurol 20(4):520–526. https://doi.org/10.1002/ANA.410200413
Becker W, Soppa U, Tejedor FJ, Walter Becker, Ulf Soppa, and Francisco Tejedor. (2014) DYRK1A: A Potential Drug Target for Multiple Down Syndrome Neuropathologies. CNS Neurol Disord: Drug Targets 13(1):26–33. https://doi.org/10.2174/18715273113126660186
Belichenko, Pavel V., Alexander M. Kleschevnikov, Ann Becker, Grant E. Wagner, Larisa V. Lysenko, Y. Eugene Yu, and William C. Mobley. 2015. “Down Syndrome Cognitive Phenotypes Modeled in Mice Trisomic for All HSA 21 Homologues.” PLoS ONE 10 (7). Doi: https://doi.org/10.1371/journal.pone.0134861.
Bernert G, Sustrova M, Sovcikova E, Seidl R, Lubec G (2001) “Effects of a Single Transdermal Nicotine Dose on Cognitive Performance in Adults with Down Syndrome”. Journal of Neural Transmission. Supplementum, 61:237–245. https://doi.org/10.1007/978-3-7091-6262-0_19
Bose, Anindita, and M. Flint Beal. 2016. “Mitochondrial Dysfunction in Parkinson’s Disease.” Journal of Neurochemistry 139 Suppl 1 (October): 216–31. Doi: https://doi.org/10.1111/JNC.13731.
Bourgonje AR, Feelisch M, Faber KN, Pasch A, Dijkstra G, van Goor H (2020) Oxidative Stress and Redox-Modulating Therapeutics in Inflammatory Bowel Disease. Trends Mol Med 26(11):1034–1046. https://doi.org/10.1016/J.MOLMED.2020.06.006
Buczyńska A, Sidorkiewicz I, Ławicki S, Krętowski AJ, Zbucka-Krętowska M (2021) Prenatal Screening of Trisomy 21: Could Oxidative Stress Markers Play a Role? J Clin Med 10(11):2382. https://doi.org/10.3390/jcm10112382
Buczyńska A, Sidorkiewicz I, Ławicki S, Krętowski A, Zbucka-Krętowska M (2020) The Significance of Apolipoprotein E Measurement in the Screening of Fetal Down Syndrome. J Clin Med 9(12):3995. https://doi.org/10.3390/jcm9123995
Buneeva O, Fedchenko V, Kopylov A, Medvedev A (2020) Mitochondrial Dysfunction in Parkinson’s Disease: Focus on Mitochondrial DNA. Biomedicines 8(12):1–22. https://doi.org/10.3390/BIOMEDICINES8120591
Burgoyne, Kelly, Fiona J. Duff, Paula J. Clarke, Sue Buckley, Margaret J. Snowling, and Charles Hulme. 2012. “Efficacy of a Reading and Language Intervention for Children with Down Syndrome: A Randomized Controlled Trial” 53 (10): 1044–53. Doi: https://doi.org/10.1111/J.1469-7610.2012.02557.X.
Busciglio J, Pelsman A, Helguera P, Ashur-Fabian O, Pinhasov A, Brenneman D, Gozes I (2007) NAP and ADNF-9 Protect Normal and Downs Syndrome Cortical Neurons from Oxidative Damage and Apoptosis. Curr Pharm Des 13(11):1091–1098. https://doi.org/10.2174/138161207780618957
Busciglio J, Yankner BA (1995) Apoptosis and Increased Generation of Reactive Oxygen Species in down’s Syndrome Neurons in Vitro. Nature 378(6559):776–779. https://doi.org/10.1038/378776a0
Capsoni, Simona, and Antonino Cattaneo. 2022. “Getting Into the Brain: The Intranasal Approach to Enhance the Delivery of Nerve Growth Factor and Its Painless Derivative in Alzheimer’s Disease and Down Syndrome.” Frontiers in Neuroscience 16 (March). Doi: https://doi.org/10.3389/FNINS.2022.773347.
Cenini G, Dowling ALS, Beckett TL, Barone E, Mancuso C, Murphy MP, LeVine H et al (2012) Association between Frontal Cortex Oxidative Damage and Beta-Amyloid as a Function of Age in Down Syndrome. Biochimica Et Biophysica Acta - Molecular Basis of Disease 1822(2):130–138. https://doi.org/10.1016/J.BBADIS.2011.10.001
Choi HK, Chung KC (2011) Dyrk1A Positively Stimulates ASK1-JNK Signaling Pathway during Apoptotic Cell Death. Experimental Neurobiology 20(1):35. https://doi.org/10.5607/EN.2011.20.1.35
Choong, Xun Yu, Justin L. Tosh, Laura J. Pulford, and Elizabeth M.C. Fisher. 2015. “Dissecting Alzheimer Disease in Down Syndrome Using Mouse Models.” Frontiers in Behavioral Neuroscience 9 (OCT). Doi: https://doi.org/10.3389/FNBEH.2015.00268.
Convertini P, Menga A, Andria G, Scala I, Santarsiero A, Castiglione MA, Morelli VI, Infantino V (2016) The Contribution of the Citrate Pathway to Oxidative Stress in Down Syndrome. Immunology 149(4):423–431. https://doi.org/10.1111/IMM.12659
Coskun, Pinar E., and Jorge Busciglio. 2012. “Oxidative Stress and Mitochondrial Dysfunction in Down’s Syndrome: Relevance to Aging and Dementia.” Current Gerontology and Geriatrics Research 2012. Doi: https://doi.org/10.1155/2012/383170.
Costa ACS, Brandão AC, Boada R, Barrionuevo VL, Taylor HG, Roth E, Stasko MR et al (2022) Safety, Efficacy, and Tolerability of Memantine for Cognitive and Adaptive Outcome Measures in Adolescents and Young Adults with Down Syndrome: A Randomised, Double-Blind, Placebo-Controlled Phase 2 Trial. The Lancet Neurology 21(1):31–41. https://doi.org/10.1016/S1474-4422(21)00369-0
Curtis ME, Daohai Yu, Praticò D (2020) Dysregulation of the Retromer Complex System in Down Syndrome. Ann Neurol 88(1):137–147. https://doi.org/10.1002/ANA.25752
Das I, Reeves RH (2011) The Use of Mouse Models to Understand and Improve Cognitive Deficits in Down Syndrome. Dis Model Mech 4(5):596–606. https://doi.org/10.1242/DMM.007716
de Graaf G, Buckley F, Dever J, Skotko BG (2017) Estimation of Live Birth and Population Prevalence of Down Syndrome in Nine U.S. States. Am J Med Genet A 173(10):2710–2719. https://doi.org/10.1002/AJMG.A.38402
de Graaf G, Buckley F, Skotko BG (2021) Estimation of the Number of People with Down Syndrome in Europe. European Journal of Human Genetics : EJHG 29(3):402–410. https://doi.org/10.1038/S41431-020-00748-Y
Dick MB, Doran E, Phelan M, Lott IT (2016) Cognitive Profiles on the Severe Impairment Battery Are Similar in Alzheimer Disease and Down Syndrome With Dementia. Alzheimer Dis Assoc Disord 30(3):251–257. https://doi.org/10.1097/WAD.0000000000000132
Domenico, Fabio Di, Antonella Tramutola, Eugenio Barone, Chiara Lanzillotta, Olivia Defever, Andrea Arena, Ilaria Zuliani, et al. 2019. “Restoration of Aberrant MTOR Signaling by Intranasal Rapamycin Reduces Oxidative Damage: Focus on HNE-Modified Proteins in a Mouse Model of down Syndrome.” Redox Biology 23 (May). Doi: https://doi.org/10.1016/J.REDOX.2019.101162.
“Down Syndrome and Beta-Amyloid Deposition : Current Opinion in Neurology.” 2004. Current Opinion in Neurology 17: 95–100. https://journals.lww.com/co-neurology/Fulltext/2004/04000/Down_syndrome_and_beta_amyloid_deposition.3.aspx.
Duchon, Arnaud, and Yann Herault. 2016. “DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in down Syndrome.” Frontiers in Behavioral Neuroscience 10 (JUN): 104. Doi: https://doi.org/10.3389/FNBEH.2016.00104/BIBTEX.
Duval, Nathan, Guido N. Vacano, and David Patterson. 2018. “Rapamycin Treatment Ameliorates Age-Related Accumulation of Toxic Metabolic Intermediates in Brains of the Ts65Dn Mouse Model of Down Syndrome and Aging.” Frontiers in Aging Neuroscience 10 (SEP). Doi: https://doi.org/10.3389/FNAGI.2018.00263.
Einor D, Bonisoli-Alquati A, Costantini D, Mousseau TA, Møller AP (2016) Ionizing Radiation, Antioxidant Response and Oxidative Damage: A Meta-Analysis. Sci Total Environ 548–549(April):463–471. https://doi.org/10.1016/j.scitotenv.2016.01.027
Ellis R (2008) Investigating Grammatical Difficulty in Second Language Learning: Implications for Second Language Acquisition Research and Language Testing. Int J Appl Linguist 18(1):4–22. https://doi.org/10.1111/J.1473-4192.2008.00184.X
Feki, Anis, and Youssef Hibaoui. 2018. “DYRK1A Protein, A Promising Therapeutic Target to Improve Cognitive Deficits in Down Syndrome.” Brain Sciences 8 (10). Doi: https://doi.org/10.3390/BRAINSCI8100187.
Fujita K, Yamafuji M, Nakabeppu Y, Noda M (2012) Therapeutic Approach to Neurodegenerative Diseases by Medical Gases: Focusing on Redox Signaling and Related Antioxidant Enzymes. Oxid Med Cell Longev. https://doi.org/10.1155/2012/324256
Gago-Dominguez, Manuela, and Jose Esteban Castelao. 2008. “Role of Lipid Peroxidation and Oxidative Stress in the Association between Thyroid Diseases and Breast Cancer.” Critical Reviews in Oncology/Hematology. Crit Rev Oncol Hematol. Doi: https://doi.org/10.1016/j.critrevonc.2008.03.007.
Galati DF, Sullivan KD, Pham AT, Espinosa JM, Pearson CG (2018) Trisomy 21 Represses Cilia Formation and Function. Dev Cell 46(5):641. https://doi.org/10.1016/J.DEVCEL.2018.07.008
Galceran J, De Graaf K, Tejedor FJ, Becker W (2003) “The MNB/DYRK1A Protein Kinase: Genetic and Biochemical Properties”. Journal of Neural Transmission. Supplementum, 67:139–148. https://doi.org/10.1007/978-3-7091-6721-2_12
Gandhi, Sonia, and Andrey Y. Abramov. 2012. “Mechanism of Oxidative Stress in Neurodegeneration.” Oxidative Medicine and Cellular Longevity 2012. Doi: https://doi.org/10.1155/2012/428010.
García-Cerro S, Rueda N, Vidal V, Lantigua S, Martínez-Cué C, García-Cerro S, Rueda N, Vidal V, Lantigua S, Martínez-Cué C (2017) Normalizing the Gene Dosage of Dyrk1A in a Mouse Model of Down Syndrome Rescues Several Alzheimer’s Disease Phenotypes. Neurobiol Dis 106(October):76–88. https://doi.org/10.1016/J.NBD.2017.06.010
Gardiner, Katheleen J. 2014. “Pharmacological Approaches to Improving Cognitive Function in down Syndrome: Current Status and Considerations.” Drug Design, Development and Therapy. Dove Medical Press Ltd. Doi: https://doi.org/10.2147/DDDT.S51476.
Gasparovic AC, Jaganjac M, Mihaljevic B, Sunjic SB, Zarkovic N (2013) Assays for the Measurement of Lipid Peroxidation. Methods Mol Biol 965:283–293. https://doi.org/10.1007/978-1-62703-239-1_19
Gimeno A, García-Giménez JL, Audí L, Toran N, Andaluz P, Dasí F, Viña J, Pallardó FV (2014) Decreased Cell Proliferation and Higher Oxidative Stress in Fibroblasts from down Syndrome Fetuses. Preliminary Study. Biochimica Et Biophysica Acta - Molecular Basis of Disease 1842(1):116–125. https://doi.org/10.1016/j.bbadis.2013.10.014
Guedj, Fayçal, Diana W. Bianchi, and Jean Maurice Delabar. 2014. “Prenatal Treatment of Down Syndrome: A Reality?” Current Opinion in Obstetrics and Gynecology. Lippincott Williams and Wilkins. Doi: https://doi.org/10.1097/GCO.0000000000000056.
Guedj F, Siegel AE, Pennings JLA, Alsebaa F, Massingham LJ, Tantravahi U, Bianchi DW (2020) Apigenin as a Candidate Prenatal Treatment for Trisomy 21: Effects in Human Amniocytes and the Ts1Cje Mouse Model. The American Journal of Human Genetics 107(5):911–931. https://doi.org/10.1016/J.AJHG.2020.10.001
Guo CY, Sun Li, Chen XP, Zhang DS (2013) Oxidative Stress, Mitochondrial Damage and Neurodegenerative Diseases. Neural Regen Res 8(21):2003. https://doi.org/10.3969/J.ISSN.1673-5374.2013.21.009
Gupta M, Ranjitha Dhanasekaran A, Gardiner KJ (2016) Mouse Models of Down Syndrome: Gene Content and Consequences. Mammalian Genome : Official Journal of the International Mammalian Genome Society 27(11–12):538–555. https://doi.org/10.1007/S00335-016-9661-8
Hahn, Anne, and Steven Zuryn. 2019. “Mitochondrial Genome (MtDNA) Mutations That Generate Reactive Oxygen Species.” Antioxidants 8 (9). Doi: https://doi.org/10.3390/ANTIOX8090392.
Hamlett D, Eric HA, Boger AL, Kelley CM, Mufson EJ, Falangola MF, Guilfoyle DN et al (2015) Cognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome. Curr Alzheimer Res 13(1):35–52. https://doi.org/10.2174/1567205012666150921095505
Hartley D, Blumenthal T, Carrillo M, DiPaolo G, Esralew L, Gardiner K, Granholm AC et al (2015) Down Syndrome and Alzheimer’s Disease: Common Pathways, Common Goals. Alzheimer’s and Dementia 11(6):700–709. https://doi.org/10.1016/j.jalz.2014.10.007
Hasanein P, Ghafari-Vahed M, Khodadadi I (2017) Effects of Isoquinoline Alkaloid Berberine on Lipid Peroxidation, Antioxidant Defense System, and Liver Damage Induced by Lead Acetate in Rats. Redox Report : Communications in Free Radical Research 22(1):42–50. https://doi.org/10.1080/13510002.2016.1140406
He J, Li T, Chen J, Liu Y, Xiong F, Yang J, Song C (2016) Plasma Antioxidant Enzymes and Lipoperoxidation Status in Children with Down Syndrome. Clin Biochem 49(1–2):61–65. https://doi.org/10.1016/J.CLINBIOCHEM.2015.08.026
Head E, Lott IT, Wilcock DM, Lemere CA (2016) Aging in Down Syndrome and the Development of Alzheimer’s Disease Neuropathology. Curr Alzheimer Res 13(1):18–29. https://doi.org/10.2174/1567205012666151020114607
Helguera P, Seiglie J, Rodriguez J, Hanna M, Helguera G, Busciglio J (2013) Adaptive Downregulation of Mitochondrial Function in down Syndrome. Cell Metab 17(1):132–140. https://doi.org/10.1016/J.CMET.2012.12.005
Heller JH, Spiridigliozzi GA, Murali Doraiswamy P, Sullivan JA, Crissman BG, Kishnani PS (2004) Donepezil Effects on Language in Children With Down Syndrome: Results of the First 22-Week Pilot Clinical Trial†. Am J Med Genet A 130A(3):325. https://doi.org/10.1002/AJMG.A.30184
Hempel M, Cremer K, Ockeloen CW, Lichtenbelt KD, Herkert JC, Denecke J, Haack TB et al (2015) De Novo Mutations in CHAMP1 Cause Intellectual Disability with Severe Speech Impairment. Am J Hum Genet 97(3):493. https://doi.org/10.1016/J.AJHG.2015.08.003
Hibaoui Y, Grad I, Audrey Letourneau M, Sailani R, Dahoun S, Santoni FA, Gimelli S et al (2014) Modelling and Rescuing Neurodevelopmental Defect of Down Syndrome Using Induced Pluripotent Stem Cells from Monozygotic Twins Discordant for Trisomy 21. EMBO Mol Med 6(2):259–277. https://doi.org/10.1002/EMMM.201302848
Hoeffer CA, Dey A, Sachan N, Wong H, Patterson RJ, Shelton JM, Richardson JA, Klann E, Rothermel BA (2007) The Down Syndrome Critical Region Protein RCAN1 Regulates Long-Term Potentiation and Memory via Inhibition of Phosphatase Signaling. J Neurosci 27(48):13161. https://doi.org/10.1523/JNEUROSCI.3974-07.2007
Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JPA et al (2015) The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-Analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med 162(11):777–784. https://doi.org/10.7326/M14-2385
Iannello RC, Crack PJ, De Haan JB, Kola I (1999) Oxidative Stress and Neural Dysfunction in Down Syndrome. J Neural Transm Suppl 57(57):257–267. https://doi.org/10.1007/978-3-7091-6380-1_17
Ioannou MS, Jackson J, Sheu S-H, Hess HF, Lippincott-Schwartz J, Liu Z (2019) Neuron-Astrocyte Metabolic Coupling Protects against Activity-Induced Fatty Acid Toxicity. Cell 177:1522-1535.e14. https://doi.org/10.1016/j.cell.2019.04.001
Iqbal, Mohamed Ariff, and Eftekhar Eftekharpour. 2017. “Regulatory Role of Redox Balance in Determination of Neural Precursor Cell Fate.” Stem Cells International 2017. Doi: https://doi.org/10.1155/2017/9209127.
Irving C, Basu A, Richmond S, Burn J, Wren C (2008) Twenty-Year Trends in Prevalence and Survival of Down Syndrome. European Journal of Human Genetics : EJHG 16(11):1336–1340. https://doi.org/10.1038/EJHG.2008.122
Ishihara, Keiichi, and Satoshi Akiba. 2017. “A Comprehensive Diverse ‘-Omics’ Approach to Better Understanding the Molecular Pathomechanisms of Down Syndrome.” Brain Sciences 7 (4). Doi: https://doi.org/10.3390/BRAINSCI7040044.
Ishihara K, Amano K, Takaki E, Ebrahim AS, Shimohata A, Shibazaki N, Inoue I et al (2009) Increased Lipid Peroxidation in Down’s Syndrome Mouse Models. J Neurochem 110(6):1965–1976. https://doi.org/10.1111/J.1471-4159.2009.06294.X
Izzo A, Manco R, Bonfiglio F, Calì G, de Cristofaro T, Patergnani S, Cicatiello R et al (2014) NRIP1/RIP140 SiRNA-Mediated Attenuation Counteracts Mitochondrial Dysfunction in Down Syndrome. Hum Mol Genet 23(16):4406–4419. https://doi.org/10.1093/HMG/DDU157
Izzo, Antonella, Rosanna Manco, Tiziana De Cristofaro, Ferdinando Bonfiglio, Rita Cicatiello, Nunzia Mollo, Marco De Martino, et al. 2017. “Overexpression of Chromosome 21 MiRNAs May Affect Mitochondrial Function in the Hearts of Down Syndrome Fetuses.” International Journal of Genomics 2017. Doi: https://doi.org/10.1155/2017/8737649.
Izzo, Antonella, Nunzia Mollo, Maria Nitti, Simona Paladino, Gaetano Calì, Rita Genesio, Ferdinando Bonfiglio, et al. 2018. Mitochondrial Dysfunction in down Syndrome: Molecular Mechanisms and Therapeutic Targets. Molecular Medicine. Vol. 24. BioMed Central Ltd. Doi: https://doi.org/10.1186/s10020-018-0004-y.
Jackson A, Maybee J, Wolter-Warmerdam K, DeBoer E, Hickey F (2019) Associations between Age, Respiratory Comorbidities, and Dysphagia in Infants with down Syndrome. Pediatr Pulmonol 54(11):1853–1859. https://doi.org/10.1002/ppul.24458
Ježek, Jan, Katrina F. Cooper, and Randy Strich. 2018. “Reactive Oxygen Species and Mitochondrial Dynamics: The Yin and Yang of Mitochondrial Dysfunction and Cancer Progression.” Antioxidants 7 (1). Doi: https://doi.org/10.3390/ANTIOX7010013.
Juan, Celia Andrés, José Manuel Pérez de la Lastra, Francisco J. Plou, and Eduardo Pérez-Lebeña. 2021. “The Chemistry of Reactive Oxygen Species (ROS) Revisited: Outlining Their Role in Biological Macromolecules (DNA, Lipids and Proteins) and Induced Pathologies.” International Journal of Molecular Sciences 2021, Vol. 22, Page 4642 22 (9): 4642. Doi: https://doi.org/10.3390/IJMS22094642.
Keck-Wherley J, Grover D, Bhattacharyya S, Xiufen Xu, Holman D, Lombardini ED, Verma R, Biswas R, Galdzicki Z (2011) Abnormal MicroRNA Expression in Ts65Dn Hippocampus and Whole Blood: Contributions to down Syndrome Phenotypes. Dev Neurosci 33(5):451–467. https://doi.org/10.1159/000330884
Kim SH, Vlkolinsky R, Cairns N, Fountoulakis M, Lubec G (2001) The Reduction of NADH Ubiquinone Oxidoreductase 24- and 75-KDa Subunits in Brains of Patients with Down Syndrome and Alzheimer’s Disease. Life Sci 68(24):2741–2750. https://doi.org/10.1016/S0024-3205(01)01074-8
Kimura, Ryo, Kouzin Kamino, Takashi Kudo, and Masatoshi Takeda. 2006. “P1–383: DYRK1A up–Regulated by Aβ and Oxidative Stress, Is Significantly Overexpressed in the Brain with Alzheimer’s Disease.” Alzheimer’s & Dementia 2 (3S_Part_7): S210–S210. Doi: https://doi.org/10.1016/J.JALZ.2006.05.761.
Knobloch, Marlen, and Sebastian Jessberger. 2017. “Metabolism and Neurogenesis.” Doi: https://doi.org/10.1016/j.conb.2016.11.006.
Komatsu, Tomoko, Yoon Duckyoung, Ayumi Ito, Kenji Kurosawa, Yojiro Maehata, Tomoko Kubodera, Masakazu Ikeda, and Masaichi Chnag Il Lee. 2013. “Increased Oxidative Stress Biomarkers in the Saliva of Down Syndrome Patients” 58 (9): 1246–50. https://pubmed.ncbi.nlm.nih.gov/23714170/.
Korbel JO, Tirosh-Wagner T, Urban AE, Chen XN, Kasowski M, Dai Li, Grubert F et al (2009) The Genetic Architecture of Down Syndrome Phenotypes Revealed by High-Resolution Analysis of Human Segmental Trisomies. Proc Natl Acad Sci USA 106(29):12031–12036. https://doi.org/10.1073/PNAS.0813248106
Korenberg JR, Chen XN, Schipper R, Sun Z, Gonsky R, Gerwehr S, Carpenter N et al (1994) Down Syndrome Phenotypes: The Consequences of Chromosomal Imbalance. Proc Natl Acad Sci USA 91(11):4997–5001. https://doi.org/10.1073/pnas.91.11.4997
Kuehn, Bridget M. 2016. Treating Trisomies: Prenatal Down’s Syndrome Therapies Explored in Mice. Nature Medicine. Vol. 22. Nature Publishing Group. https://pubmed.ncbi.nlm.nih.gov/26735397/.
Kumar J, Haldar C, Verma R, Jitendra Kumar, Chandana Haldar, and Rakesh Verma. (2020) Fluoride Compromises Testicular Redox Sensor, Gap Junction Protein, and Metabolic Status: Amelioration by Melatonin. Biol Trace Elem Res 196(2):552–564. https://doi.org/10.1007/S12011-019-01946-6
Kumar GP, Khanum F (2012) Neuroprotective Potential of Phytochemicals. Pharmacogn Rev 6(12):81. https://doi.org/10.4103/0973-7847.99898
Kura B, Bagchi AK, Singal PK, Barancik M, Lebaron TW, Valachova K, Šoltés L, Slezák J (2019) Molecular Hydrogen: Potential in Mitigating Oxidative-Stress-Induced Radiation Injury. Can J Physiol Pharmacol 97(4):287–292. https://doi.org/10.1139/CJPP-2018-0604
Kurabayashi N, Nguyen MD, Sanada K (2019) Triple Play of DYRK1A Kinase in Cortical Progenitor Cells of Trisomy 21. Neurosci Res 138(January):19–25. https://doi.org/10.1016/J.NEURES.2018.09.007
la Torre R, de, Susana de Sola, Gimena Hernandez, Magí Farré, Jesus Pujol, Joan Rodriguez, Josep María Espadaler, et al (2016) Safety and Efficacy of Cognitive Training plus Epigallocatechin-3-Gallate in Young Adults with Down’s Syndrome (TESDAD): A Double-Blind, Randomised, Placebo-Controlled, Phase 2 Trial. The Lancet Neurology 15(8):801–810. https://doi.org/10.1016/S1474-4422(16)30034-5
la Torre R, De SD, Sola MP, Duchon A, Martínez M, de Lagran M, Farré MF et al (2014) Epigallocatechin-3-Gallate, a DYRK1A Inhibitor, Rescues Cognitive Deficits in Down Syndrome Mouse Models and in Humans. Mol Nutr Food Res 58(2):278–288. https://doi.org/10.1002/MNFR.201300325
Lana-Elola, Eva, Sheona D. Watson-Scales, Elizabeth M.C. Fisher, and Victor L.J. Tybulewicz. 2011. “Down Syndrome: Searching for the Genetic Culprits.” DMM Disease Models and Mechanisms. Company of Biologists. Doi: https://doi.org/10.1242/dmm.008078.
Lazarov, Orly, and Michael P. Demars. 2012. “All in the Family: How the APPs Regulate Neurogenesis.” Frontiers in Neuroscience 6 (JUN): 1–21. Doi: https://doi.org/10.3389/FNINS.2012.00081.
Lee JE, Jang H, Cho EJ, Youn HD (2009) Down Syndrome Critical Region 1 Enhances the Proteolytic Cleavage of Calcineurin. Exp Mol Med 41(7):471–477. https://doi.org/10.3858/EMM.2009.41.7.052
Lee SE, Duran-Martinez M, Khantsis S, Bianchi DW, Guedj F (2020) Challenges and Opportunities for Translation of Therapies to Improve Cognition in Down Syndrome. Trends Mol Med 26(2):150–169. https://doi.org/10.1016/J.MOLMED.2019.10.001/ATTACHMENT/CCE4B6F5-EDC2-4D0E-B85B-0AE40E5D0A3D/MMC1.MP4
Liu, Yansheng, Christelle Borel, Li Li, Torsten Müller, Evan G. Williams, Pierre Luc Germain, Marija Buljan, et al. 2017. “Systematic Proteome and Proteostasis Profiling in Human Trisomy 21 Fibroblast Cells.” Nature Communications 8 (1). Doi: https://doi.org/10.1038/S41467-017-01422-6.
Liu, Zewen, Tingyang Zhou, Alexander C. Ziegler, Peter Dimitrion, and Li Zuo. 2017. “Oxidative Stress in Neurodegenerative Diseases: From Molecular Mechanisms to Clinical Applications.” Oxidative Medicine and Cellular Longevity 2017. Doi: https://doi.org/10.1155/2017/2525967.
Liu Z, Zhu Z, Zhao J, Ren W, Cai Y, Wang Q, Luan X, Zhao K, He J (2017c) Malondialdehyde: A Novel Predictive Biomarker for Post-Stroke Depression. J Affect Disord 220(October):95–101. https://doi.org/10.1016/j.jad.2017.05.023
Long R, Drawbaugh ML, Davis CM, Goodlett CR, Williams JR, Roper RJ (2019) Usage of and Attitudes about Green Tea Extract and Epigallocathechin-3-Gallate (EGCG) as a Therapy in Individuals with Down Syndrome. Complement Ther Med 45(August):234–241. https://doi.org/10.1016/J.CTIM.2019.07.002
Lott IT (2012) Antioxidants in Down Syndrome. Elsevier, Biochimica et Biophysica Acta - Molecular Basis of Disease. https://doi.org/10.1016/j.bbadis.2011.12.010
Lott IT, Dierssen M (2010) Cognitive Deficits and Associated Neurological Complications in Individuals with Down’s Syndrome. The Lancet Neurology 9(6):623–633. https://doi.org/10.1016/S1474-4422(10)70112-5
Lott IT, Doran E, Nguyen VQ, Tournay A, Head E, Gillen DL (2011) Down Syndrome and Dementia: A Randomized, Controlled Trial of Antioxidant Supplementation. Am J Med Genet A 155A(8):1939. https://doi.org/10.1002/AJMG.A.34114
Lott IT, Head E (2001) Down Syndrome and Alzheimer’s Disease: A Link between Development and Aging. Ment Retard Dev Disabil Res Rev 7(3):172–178. https://doi.org/10.1002/MRDD.1025
Lu, Jie, Giuseppe Esposito, Caterina Scuderi, Luca Steardo, Laurent C. Delli-Bovi, Jonathan L. Hecht, Bryan C. Dickinson, Christopher J. Chang, Takashi Mori, and Volney Sheen. 2011. “S100B and APP Promote a Gliocentric Shift and Impaired Neurogenesis in Down Syndrome Neural Progenitors.” PloS One 6 (7). Doi: https://doi.org/10.1371/JOURNAL.PONE.0022126.
Lu, Jie, Volney Sheen, and Volney Shee. 2013. Genetic and Epigenetic Mechanisms in Down Syndrome Brain. Down Syndrome. IntechOpen. Doi: https://doi.org/10.5772/52807.
Lu, Xiaoxiang, Jiajie Yang, and Yangfei Xiang. 2022. “Modeling Human Neurodevelopmental Diseases with Brain Organoids.” Cell Regeneration 2022 11:1 11 (1): 1–13. Doi: https://doi.org/10.1186/S13619-021-00103-6.
Ma Q (2013) Role of Nrf2 in Oxidative Stress and Toxicity. Annu Rev Pharmacol Toxicol 53(January):401–426. https://doi.org/10.1146/ANNUREV-PHARMTOX-011112-140320
Mai CT, Isenburg JL, Canfield MA, Meyer RE, Correa A, Alverson CJ, Lupo PJ et al (2019) National Population-Based Estimates for Major Birth Defects, 2010–2014. Birth Defects Research 111(18):1420–1435. https://doi.org/10.1002/bdr2.1589
Manap, Aimi Syamima Abdul, Amelia Cheng Wei Tan, Weng Hhin Leong, Adeline Yoke Yin Chia, Shantini Vijayabalan, Aditya Arya, Eng Hwa Wong, et al. 2019. “Synergistic Effects of Curcumin and Piperine as Potent Acetylcholine and Amyloidogenic Inhibitors with Significant Neuroprotective Activity in Sh-Sy5y Cells via Computational Molecular Modeling and in Vitro Assay.” Frontiers in Aging Neuroscience 10 (JUL): 206. Doi: https://doi.org/10.3389/FNAGI.2019.00206/BIBTEX.
Manna C, Officioso A, Trojsi F, Tedeschi G, Leoncini S, Signorini C, Ciccoli L, De Felice C (2016) Increased Non-Protein Bound Iron in Down Syndrome: Contribution to Lipid Peroxidation and Cognitive Decline. Free Radical Res 50(12):1422–1431. https://doi.org/10.1080/10715762.2016.1253833
Marcovecchio GE, Ferrua F, Fontana E, Beretta S, Genua M, Bortolomai I, Conti A et al (2021) Premature Senescence and Increased Oxidative Stress in the Thymus of Down Syndrome Patients. Front Immunol 12(June):1830. https://doi.org/10.3389/FIMMU.2021.669893/BIBTEX
Marechal D, Brault V, Leon A, Martin D, Pereira PL, Loaëc N, Birling MC, Friocourt G, Blondel M, Herault Y (2019) Cbs Overdosage Is Necessary and Sufficient to Induce Cognitive Phenotypes in Mouse Models of Down Syndrome and Interacts Genetically with Dyrk1a. Hum Mol Genet 28(9):1561–1577. https://doi.org/10.1093/HMG/DDY447
Marnett LJ (2002) Oxy Radicals, Lipid Peroxidation and DNA Damage. Toxicology 181–182(December):219–222. https://doi.org/10.1016/S0300-483X(02)00448-1
Martinez JL, Zammit MD, West NR, Christian BT, Bhattacharyya A (2021) Basal Forebrain Cholinergic Neurons: Linking Down Syndrome and Alzheimer’s Disease. Frontiers in Aging Neuroscience 13(July):406. https://doi.org/10.3389/FNAGI.2021.703876/BIBTEX
Meng, Xiao-Wei, Jie Wang, and Qing-Wen Ma. 2018. “The Genetic Background and Application of Down Syndrome Mouse Models.” Yi Chuan = Hereditas 40 (3): 207–17. Doi: https://doi.org/10.16288/j.yczz.17-279.
Mok, Kin Y., Emma L. Jones, Marisa Hanney, Denise Harold, Rebecca Sims, Julie Williams, Clive Ballard, and John Hardy. 2014. “Polymorphisms in BACE2 May Affect the Age of Onset Alzheimer’s Dementia in Down Syndrome” 35 (6). Doi: https://doi.org/10.1016/J.NEUROBIOLAGING.2013.12.022.
Moldrich RX, Lainé J, Visel A, Beart PM, Laffaire J, Rossier J, Potier MC (2008) Transmembrane Protein 50b (C21orf4), a Candidate for Down Syndrome Neurophenotypes, Encodes an Intracellular Membrane Protein Expressed in the Rodent Brain. Neuroscience 154(4):1255–1266. https://doi.org/10.1016/J.NEUROSCIENCE.2008.01.089
Muchová, J., I. Žitňanová, and Z. Ďuračková. 2014. “Oxidative Stress and Down Syndrome. Do Antioxidants Play a Role in Therapy?” Physiological Research. Czech Academy of Sciences.
Müller S, Chakrapani BPS, Schwegler H, Hofmann H-D, Kirsch M (2009) Neurogenesis in the Dentate Gyrus Depends on Ciliary Neurotrophic Factor and Signal Transducer and Activator of Transcription 3 Signaling. Stem Cells (dayton, Ohio) 27(2):431–441. https://doi.org/10.1634/STEMCELLS.2008-0234
Murthy SK, Malhotra AK, Mani S, Maryam EA, Shara EE, Al-Rowaished M, Naveed S, Alkhayat AI, Alali MT (2007) Incidence of Down Syndrome in Dubai, UAE. Medical Principles and Practice : International Journal of the Kuwait University, Health Science Centre 16(1):25–28. https://doi.org/10.1159/000096136
Mustafa Nachvak S, Reza Neyestani T, Ali Mahboob S, Sabour S, Ali Keshawarz S, Speakman JR (2014) α-Tocopherol Supplementation Reduces Biomarkers of Oxidative Stress in Children with Down Syndrome: A Randomized Controlled Trial. Eur J Clin Nutr 68(10):1119–1123. https://doi.org/10.1038/ejcn.2014.97
Najas S, Arranz J, Lochhead PA, Ashford AL, Oxley D, Delabar JM, Cook SJ, Barallobre MJ, Arbonés ML (2015) DYRK1A-Mediated Cyclin D1 Degradation in Neural Stem Cells Contributes to the Neurogenic Cortical Defects in Down Syndrome. EBioMedicine 2(2):120–134. https://doi.org/10.1016/J.EBIOM.2015.01.010
Narasimhan K, Lin SL, Tong T, Baig S, Ho S, Sukumar P, Biswas A, Hahn S, Bajic VB, Choolani M (2013) Maternal Serum Protein Profile and Immune Response Protein Subunits as Markers for Non-Invasive Prenatal Diagnosis of Trisomy 21, 18, and 13. Prenat Diagn 33(3):223–231. https://doi.org/10.1002/pd.4047
Netto CB, Siqueira IR, Fochesatto C, Portela LV, Da Purificação M, Tavares DO, Souza RG, Gonçalves CA (2004) S100B Content and SOD Activity in Amniotic Fluid of Pregnancies with Down Syndrome. Clin Biochem 37(2):134–137. https://doi.org/10.1016/j.clinbiochem.2003.09.010
Nguyen KV (2019) β-Amyloid Precursor Protein (APP) and the Human Diseases. AIMS Neuroscience 6(4):273. https://doi.org/10.3934/NEUROSCIENCE.2019.4.273
Nishizawa, Hironari, Mitsuyo Matsumoto, Guan Chen, Yusho Ishii, Keisuke Tada, Masafumi Onodera, Hiroki Kato, Akihiko Muto, Kozo Tanaka, and Kazuhiko Igarashi. 2021. “Lipid Peroxidation and the Subsequent Cell Death Transmitting from Ferroptotic Cells to Neighboring Cells.” Cell Death & Disease 2021 12:4 12 (4): 1–14. Doi: https://doi.org/10.1038/s41419-021-03613-y.
Nunomura A, Perry G, Pappolla MA, Friedland RP, Hirai K, Chiba S, Smith MA (2000) Neuronal Oxidative Stress Precedes Amyloid-β Deposition in down Syndrome. J Neuropathol Exp Neurol 59(11):1011–1017. https://doi.org/10.1093/jnen/59.11.1011
Olmos-Serrano, Jose Luis, Hyo Jung Kang, William A. Tyler, John C. Silbereis, Feng Cheng, Ying Zhu, Mihovil Pletikos, et al. 2016. “Down Syndrome Developmental Brain Transcriptome Reveals Defective Oligodendrocyte Differentiation and Myelination.” Neuron 89 (6). Doi: https://doi.org/10.1016/J.NEURON.2016.01.042.
Onnivello, Sara, Francesca Pulina, Chiara Locatelli, Chiara Marcolin, Giuseppe Ramacieri, Francesca Antonaros, Beatrice Vione, Maria Caracausi, and Silvia Lanfranchi. 2022. “Cognitive Profiles in Children and Adolescents with Down Syndrome.” Scientific Reports 2022 12:1 12 (1): 1–14. Doi: https://doi.org/10.1038/s41598-022-05825-4.
Ordonez J, Francisco, and Manuel Rosety-Rodriguez. (2007) Regular Exercise Attenuated Lipid Peroxidation in Adolescents with Down’s Syndrome. Clin Biochem 40(1–2):141–142. https://doi.org/10.1016/J.CLINBIOCHEM.2006.09.013
Ozcan S, Kelestemur MM, Hekim MG, Bulmus O, Bulut F, Bilgin B, Canpolat S, Ozcan M (2022) Asprosin, a Novel Therapeutic Candidate for Painful Neuropathy: An Experimental Study in Mice. Naunyn-Schmiedeberg’s Arch Pharmacol 395(3):325–335. https://doi.org/10.1007/S00210-021-02197-W
Pagano G, Castello G (2012) Oxidative Stress and Mitochondrial Dysfunction in Down Syndrome. Adv Exp Med Biol 724:291–299. https://doi.org/10.1007/978-1-4614-0653-2_22
Pallardó, Federico V., Ana Lloret, Michel Lebel, Marco D’Ischia, Victoria C. Cogger, David G. Le Couteur, Maria Nicola Gadaleta, Giuseppe Castello, and Giovanni Pagano. 2010. “Mitochondrial Dysfunction in Some Oxidative Stress-Related Genetic Diseases: Ataxia-Telangiectasia, Down Syndrome, Fanconi Anaemia and Werner Syndrome.” Biogerontology 2010 11:4 11 (4): 401–19. Doi: https://doi.org/10.1007/S10522-010-9269-4.
Pardridge WM (2007) Blood-Brain Barrier Delivery. Drug Discovery Today 12(1–2):54–61. https://doi.org/10.1016/J.DRUDIS.2006.10.013
Parfieniuk E, Samczuk P, Kowalczyk T, Pietrowska K, Niemira M, Paczkowska-Abdulsalam M, Wolczynski S, Kretowski A, Ciborowski M, Zbucka-Kretowska M (2018) Maternal Plasma Metabolic Fingerprint Indicative for Fetal Down Syndrome. Prenat Diagn 38(11):876–882. https://doi.org/10.1002/pd.5345
Perluigi, Marzia, and D. Allan Butterfield. 2012. “Oxidative Stress and Down Syndrome: A Route toward Alzheimer-Like Dementia.” Current Gerontology and Geriatrics Research 2012. Doi: https://doi.org/10.1155/2012/724904.
Perluigi, Marzia, Fabio di Domenico, Ada Fiorini, Annalisa Cocciolo, Alessandra Giorgi, Cesira Foppoli, D. Allan Butterfield, et al. 2011. “Oxidative Stress Occurs Early in Down Syndrome Pregnancy: A Redox Proteomics Analysis of Amniotic Fluid.” Proteomics. Clinical Applications 5 (3–4): 167–78. www.clinical.proteomics-journal.com.
Perrone S, Longini M, Bellieni CV, Centini G, Kenanidis A, De Marco L, Petraglia F, Buonocore G (2007) Early Oxidative Stress in Amniotic Fluid of Pregnancies with Down Syndrome. Clin Biochem 40(3–4):177–180. https://doi.org/10.1016/j.clinbiochem.2006.10.019
Picca A, Calvani R, Coelho-Júnior HJ, Landi F, Bernabei R, Marzetti E (2020) Mitochondrial Dysfunction, Oxidative Stress, and Neuroinflammation: Intertwined Roads to Neurodegeneration. Antioxidants (basel, Switzerland) 9(8):1–21. https://doi.org/10.3390/ANTIOX9080647
Pietryga M, Tobola-Wrobel K, Dydowicz P, Radzicka-Mularczyk S, Ziolkowska K, Napierala M, Florek E, Brazert J (2021) Can Redox Imbalance Predict Abnormal Foetal Development? Ginekol Pol. https://doi.org/10.5603/GP.A2021.0122
Bally P, Blandine, and Keith K. Murai. (2021) Astrocytes in Down Syndrome Across the Lifespan. Front Cell Neurosci 15(August):334. https://doi.org/10.3389/FNCEL.2021.702685/BIBTEX
Prandini P, Deutsch S, Lyle R, Gagnebin M, Vivier CD, Delorenzi M, Gehrig C et al (2007) Natural Gene-Expression Variation in Down Syndrome Modulates the Outcome of Gene-Dosage Imbalance. Am J Hum Genet 81(2):252–263. https://doi.org/10.1086/519248
Ramana, Kota V., Sanjay Srivastava, and Sharad S. Singhal. 2017. “Lipid Peroxidation Products in Human Health and Disease 2016.” Oxidative Medicine and Cellular Longevity. Hindawi Limited. Doi: https://doi.org/10.1155/2017/2163285.
Revilla NR, Martínez-Cué C (2020) Antioxidants in down Syndrome: From Preclinical Studies to Clinical Trials. Antioxidants 9(8):1–23. https://doi.org/10.3390/antiox9080692
Rosenbloom M, Barclay T, Johnsen J, Erickson L, Svitak A, Pyle M, Frey W, Hanson LR (2020) Double-Blind Placebo-Controlled Pilot Investigation of the Safety of a Single Dose of Rapid-Acting Intranasal Insulin in Down Syndrome. Drugs r&d 20(1):11–15. https://doi.org/10.1007/S40268-020-00296-2
Rueda, Noemí, Jesús Flórez, and Carmen Martínez-Cué. 2012. “Mouse Models of down Syndrome as a Tool to Unravel the Causes of Mental Disabilities.” Neural Plasticity 2012. Doi: https://doi.org/10.1155/2012/584071.
Salehi A, Faizi M, Belichenko PV, Mobley WC (2007) Using Mouse Models to Explore Genotype-Phenotype Relationship in Down Syndrome. Ment Retard Dev Disabil Res Rev 13(3):207–214. https://doi.org/10.1002/MRDD.20164
Sánchez-Font MF, Bosch-Comas A, Gonzàlez-Duarte R, Marfany G (2003) Overexpression of FABP7 in Down Syndrome Fetal Brains Is Associated with PKNOX1 Gene-dosage Imbalance. Nucleic Acids Res 31(11):2769–2777. https://doi.org/10.1093/NAR/GKG396
Schiavo JH (2019) PROSPERO: An International Register of Systematic Review Protocols. Med Ref Serv Q 38(2):171–180. https://doi.org/10.1080/02763869.2019.1588072
Schupf N, Zigman WB, Tang MX, Pang D, Mayeux R, Mehta P, Silverman W (2010) Change in Plasma Aβ Peptides and Onset of Dementia in Adults with Down Syndrome. Neurology 75(18):1639–1644. https://doi.org/10.1212/WNL.0B013E3181FB448B
Scott, H., T. J. Phillips, Y. Sze, A. Alfieri, M. F. Rogers, V. Volpato, C. P. Case, and P. J. Brunton. 2020. “Maternal Antioxidant Treatment Prevents the Adverse Effects of Prenatal Stress on the Offspring’s Brain and Behavior.” Neurobiology of Stress 13 (November). Doi: https://doi.org/10.1016/J.YNSTR.2020.100281.
Sharifi-Rad M, Anil NV, Kumar PZ, Varoni EM, Dini L, Panzarini E, Rajkovic J et al (2020) Lifestyle, Oxidative Stress, and Antioxidants: Back and Forth in the Pathophysiology of Chronic Diseases. Front Physiol 11(July):694. https://doi.org/10.3389/FPHYS.2020.00694/BIBTEX
Sherman, Stephanie L., Emily G. Allen, Lora H. Bean, and Sallie B. Freeman. 2007. “Epidemiology of Down Syndrome.” Mental Retardation and Developmental Disabilities Research Reviews. Ment Retard Dev Disabil Res Rev. Doi: https://doi.org/10.1002/mrdd.20157.
Shichiri M, Yoshida Y, Ishida N, Hagihara Y, Iwahashi H, Tamai H, Niki E (2011) α-Tocopherol Suppresses Lipid Peroxidation and Behavioral and Cognitive Impairments in the Ts65Dn Mouse Model of Down Syndrome. Free Radical Biol Med 50(12):1801–1811. https://doi.org/10.1016/j.freeradbiomed.2011.03.023
Silverman, Wayne. 2007. “Down Syndrome: Cognitive Phenotype.” Mental Retardation and Developmental Disabilities Research Reviews. Ment Retard Dev Disabil Res Rev. Doi: https://doi.org/10.1002/mrdd.20156.
Singh, Anju, Ritushree Kukreti, Luciano Saso, and Shrikant Kukreti. 2019. “Oxidative Stress: A Key Modulator in Neurodegenerative Diseases.” Molecules 24 (8). Doi: https://doi.org/10.3390/MOLECULES24081583.
Slonim, Donna K., Keiko Koide, Kirby L. Johnson, Umadevi Tantravahi, Janet M. Cowan, Zina Jarrah, and Diana W. Bianchi. 2009. “Functional Genomic Analysis of Amniotic Fluid Cell-Free MRNA Suggests That Oxidative Stress Is Significant in Down Syndrome Fetuses” 106 (23): 9425–29. https://www.pnas.org/content/106/23/9425.
Sobol, Maria, Joakim Klar, Loora Laan, Mansoureh Shahsavani, Jens Schuster, Göran Annerén, Anne Konzer, et al. 2019. “Transcriptome and Proteome Profiling of Neural Induced Pluripotent Stem Cells from Individuals with Down Syndrome Disclose Dynamic Dysregulations of Key Pathways and Cellular Functions.” Molecular Neurobiology 56 (10). https://link.springer.com/article/https://doi.org/10.1007/s12035-019-1585-3.
Souchet, Benoit, Fayçal Guedj, Zsuza Penke-Verdier, Fabrice Daubigney, Arnaud Duchon, Yann Herault, Jean Charles Bizot, et al. 2015. “Pharmacological Correction of Excitation/Inhibition Imbalance in Down Syndrome Mouse Models.” Frontiers in Behavioral Neuroscience 9 (OCTOBER). Doi: https://doi.org/10.3389/FNBEH.2015.00267.
Stagni F, Giacomini A, Emili M, Trazzi S, Guidi S, Sassi M, Ciani E, Rimondini R, Bartesaghi R (2016) Short- and Long-Term Effects of Neonatal Pharmacotherapy with Epigallocatechin-3-Gallate on Hippocampal Development in the Ts65Dn Mouse Model of Down Syndrome. Neuroscience 333(October):277–301. https://doi.org/10.1016/J.NEUROSCIENCE.2016.07.031
Stagni, Fiorenza, Andrea Giacomini, Sandra Guidi, Elisabetta Ciani, and Renata Bartesaghi. 2015. “Timing of Therapies for Downsyndrome: The Sooner, the Better.” Frontiers in Behavioral Neuroscience 9 (OCT): 265. Doi: https://doi.org/10.3389/FNBEH.2015.00265/BIBTEX.
Strydom, André, Antonia Coppus, Rafael Blesa, Adrian Danek, Juan Fortea, John Hardy, Johannes Levin, et al. 2018. “Alzheimer’s Disease in Down Syndrome: An Overlooked Population for Prevention Trials.” Alzheimer’s and Dementia: Translational Research and Clinical Interventions. Elsevier Inc. Doi: https://doi.org/10.1016/j.trci.2018.10.006.
Sun, Jichao, and Subhojit Roy. 2021. “Gene-Based Therapies for Neurodegenerative Diseases.” Nature Neuroscience 2021 24:3 24 (3): 297–311. Doi: https://doi.org/10.1038/s41593-020-00778-1.
Taha, Ameer Y. 2020. “Linoleic Acid–Good or Bad for the Brain?” NPJ Science of Food 4 (1). Doi: https://doi.org/10.1038/S41538-019-0061-9.
Takano K, Goto K, Motobayashi M, Wakui K, Kawamura R, Yamaguchi T, Fukushima Y, Kosho T (2017) Early Manifestations of Epileptic Encephalopathy, Brain Atrophy, and Elevation of Serum Neuron Specific Enolase in a Boy with Beta-Propeller Protein-Associated Neurodegeneration. Eur J Med Genet 60(10):521–526. https://doi.org/10.1016/J.EJMG.2017.07.008
Timme-Laragy AR, Goldstone JV, Imhoff BR, Stegeman JJ, Hahn ME, Hansen JM (2013) Glutathione Redox Dynamics and Expression of Glutathione-Related Genes in the Developing Embryo. Free Radical Biol Med 65:89–101. https://doi.org/10.1016/j.freeradbiomed.2013.06.011
Trotsenburg AS, Van P, Vulsma T, Rutgers SL, Rozenburg-Marres V, Van Baar AL, Ridder JCD, Heymans HSA, Tijssen JGP, De Vijlder JJM (2005) The Effect of Thyroxine Treatment Started in the Neonatal Period on Development and Growth of Two-Year-Old Down Syndrome Children: A Randomized Clinical Trial. J Clin Endocrinol Metab 90(6):3304–3311. https://doi.org/10.1210/JC.2005-0130
Ullah, Hammad, Alessandro Di Minno, Cristina Santarcangelo, Haroon Khan, and Maria Daglia. 2021. “Improvement of Oxidative Stress and Mitochondrial Dysfunction by β-Caryophyllene: A Focus on the Nervous System.” Antioxidants 10 (4). Doi: https://doi.org/10.3390/ANTIOX10040546.
Valenti D, Braidy N, De Rasmo D, Signorile A, Leonardo Rossi AG, Atanasov MV, Alexandra Henrion-Caude SM, Nabavi, and R. A. Vacca. (2018) Mitochondria as Pharmacological Targets in Down Syndrome. Free Radical Biol Med 114(January):69–83. https://doi.org/10.1016/J.FREERADBIOMED.2017.08.014
Valenti, Daniela, Fiorenza Stagni, Marco Emili, Sandra Guidi, Renata Bartesaghi, and Rosa Anna Vacca. 2021. “Impaired Brain Mitochondrial Bioenergetics in the Ts65Dn Mouse Model of Down Syndrome Is Restored by Neonatal Treatment with the Polyphenol 7,8-Dihydroxyflavone.” Antioxidants 2022, Vol. 11, Page 62 11 (1): 62. Doi: https://doi.org/10.3390/ANTIOX11010062.
Walton NM, Shin R, Tajinda K, Heusner CL, Kogan JH, Miyake S, Chen Q, Tamura K, Matsumoto M (2012) Adult neurogenesis transiently generates oxidative stress. PLoS ONE 7(4):e35264. https://doi.org/10.1371/JOURNAL.PONE.0035264
Wang M, Yin C, Wang L, Liu Y, Li H, Li M, Yi X, Xiao Y (2019) Serum asprosin concentrations are increased and associated with insulin resistance in children with obesity. Ann Nutr Metab 75(4):205–212. https://doi.org/10.1159/000503808
Wang, Xinkun, and Elias K. Michaelis. 2010. “Selective Neuronal Vulnerability to Oxidative Stress in the Brain.” Frontiers in Aging Neuroscience 2 (MAR): 12. Doi: https://doi.org/10.3389/FNAGI.2010.00012/BIBTEX.
Warkad, Madhuri Shende, Chea Ha Kim, Beom Goo Kang, Soo Hyun Park, Jun Sub Jung, Jing Hui Feng, Gozde Inci, et al. 2021. “Metformin-Induced ROS Upregulation as Amplified by Apigenin Causes Profound Anticancer Activity While Sparing Normal Cells.” Scientific Reports 2021 11:1 11 (1): 1–13. Doi: https://doi.org/10.1038/s41598-021-93270-0.
Wegiel J, Gong CX, Hwang YW (2011) The role of DYRK1A in neurodegenerative diseases. FEBS J 278(2):236–245. https://doi.org/10.1111/J.1742-4658.2010.07955.X
Whitaker-Azmitia PM, Shapiro LA, Bialowas-McGoey LA (2010) Effects of S100B on serotonergic plasticity and neuroinflammation in the hippocampus in down syndrome and Alzheimer’s disease: studies in an S100b overexpressing mouse model. Cardiovasc Psychiatry Neurol. https://doi.org/10.1155/2010/153657
Whooten R, Schmitt J, Schwartz A (2018) Endocrine manifestations of Down syndrome. Curr Opin Endocrinol Diabetes Obes 25(1):61–66. https://doi.org/10.1097/MED.0000000000000382
Xu Y, Ji R, Wei R, Yin B, He F, Luo B (2016) The efficacy of hyperbaric oxygen therapy on middle cerebral artery occlusion in animal studies: a meta-analysis. PLoS ONE 11(2):e0148324
Yadav S, Kumar A, Deepika, Maurya PK (2022) Novel therapeutic approaches targeting oxidative stress in neurodegenerative diseases. In: Novel Therapeutic Approaches Targeting Oxidative Stress, pp 93–117. Academic Press
Yang W, Chen YH, Liu H, Hong Dang Qu (2015) Neuroprotective effects of piperine on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson’s disease mouse model. Int J Mol Med 36(5):1369–1376. https://doi.org/10.3892/ijmm.2015.2356
Yuan T-F, Gu S, Shan C, Marchado S, Arias-Carrión O (n.d.) Oxidative stress and adult neurogenesis. https://doi.org/10.1007/s12015-015-9603-y.
Yuan T, Yang T, Chen H, Danli Fu, Yangyang Hu, Wang J, Yuan Q, Hong Yu, Wenfeng Xu, Xie X (2019) New insights into oxidative stress and inflammation during diabetes mellitus-accelerated atherosclerosis. Redox Biol 20:247. https://doi.org/10.1016/J.REDOX.2018.09.025
Zafrilla P, Cerda B, Soler A, Xandri J, Martinez-Cachá A, Mulero J (2014). Oxidative Stress in down Syndrome. https://doi.org/10.4172/2157-7412.1000232
Zambrano JC, Marquina R, Sulbarán N, Rodríguez-Malaver AJ, Reyes RA (2009) Aerobic exercise reduced oxidative stress in saliva of persons with Down syndrome. Res Sports Med 17(3):195–203
Zamponi E, Helguera PR (2019) The shape of mitochondrial dysfunction in Down syndrome. Dev Neurobiol 79(7):613–621. https://doi.org/10.1002/DNEU.22673
Zamponi E, Zamponi N, Coskun P, Quassollo G, Lorenzo A, Cannas SA, Pigino G et al (2018) Nrf2 stabilization prevents critical oxidative damage in Down Syndrome cells. Aging Cell 17(5):e12812. https://doi.org/10.1111/ACEL.12812
Zana M, Janka Z, Kálmán J (2007) Oxidative stress: a bridge between Down’s syndrome and Alzheimer’s disease. Neurobiol Aging. https://doi.org/10.1016/j.neurobiolaging.2006.03.008
Zhang G, Wang X, Li C, Qinfeng Li YuA, An XL, Deng Y, Gillette TG, Scherer PE, Wang ZV (2021) Integrated stress response couples mitochondrial protein translation with oxidative stress control. Circulation 144(18):1500–1515. https://doi.org/10.1161/CIRCULATIONAHA.120.053125
Zhu PJ, Khatiwada S, Cui Ya, Reineke LC, Dooling SW, Kim JJ, Li W, Walter P, Costa-Mattioli M (2019) Activation of the ISR mediates the behavioral and neurophysiological abnormalities in down syndrome. Science 366(6467):843–849. https://doi.org/10.1126/SCIENCE.AAW5185
Zhu X, Zhang Yu, Yang X, Hao C, Duan H (2021) Gene Therapy for Neurodegenerative Disease: Clinical Potential and Directions. Front Mol Neurosci 14:107. https://doi.org/10.3389/FNMOL.2021.618171/BIBTEX
Zis P, Dickinson M, Shende S, Reader ZW, Strydom A (n.d.) Oxidative Stress and Memory in Adults with Down Syndrome 1 Title Page Title Oxidative Stress and Memory Decline in Adults with Down Syndrome: Longitudinal Study Enfield Integrated Learning Disability Team, 1 to 4 Riverfront, Enfield, EN1 3SY.”
Žitňanová I, Korytár P, Sobotová H, Horáková LU, Šustrová M, Pueschel S, Ďuračková Z (2006) Markers of oxidative stress in children with Down syndrome. Clin Chem Lab Med 44(3):306–310
Funding
This review was founded by internal financing of Medical University of Bialystok (SUB/1/DN/22/001/1210).
Author information
Authors and Affiliations
Contributions
Conceptualization, AB, IS, and MZK.; methodology, AB, IS, and MZK; formal analysis, AJK; data curation, AB, IS, AJK, and MZK; writing—original draft preparation, AB; writing—review and editing, IS and MZK; visualization, AB and IS; supervision, AJK and MZK; project administration, MZK; funding acquisition, MZK. All authors have read and agreed to the published version of the manuscript.
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Ethical Approval and Consent to Participate
Not applicable.
Consent for Publication
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Buczyńska, A., Sidorkiewicz, I., Krętowski, A.J. et al. The Role of Oxidative Stress in Trisomy 21 Phenotype. Cell Mol Neurobiol 43, 3943–3963 (2023). https://doi.org/10.1007/s10571-023-01417-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10571-023-01417-6